[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 360
6. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H: Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat; 2008 Aug;110(3):465-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: We examined, by immunohistochemical analysis, the expression of HIF-1alpha in normal breast tissue, benign disorders and breast cancer.
  • RESULTS: HIF-1alpha was mainly detected in tumor cell nuclei.
  • Immunoreactive nuclear HIF-1alpha was correlated with tumor size (p = 0.0013), lymph node metastasis (p = 0.0005), tumor stage (p = 0.0031) and histological grade (p = 0.0074).
  • In terms of the possible use of HIF-1alpha as a prognostic indicator, patients who had increased HIF-1alpha levels in their tumor showed shorter disease-free survival (DFS) (p < 0.0001) and overall survival (OS) (p = 0.0002) than those lacking HIF-1alpha in univariate analysis.
  • It may be useful to study the expression of HIF-1alpha using immunohistochemical analysis for better understanding of the tumor characteristics of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Diseases / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis


7. Fainstein Day P, Frohman L, Garcia Rivello H, Reubi JC, Sevlever G, Glerean M, Fernandez Gianotti T, Pietrani M, Rabadan A, Racioppi S, Bidlingmaier M: Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment. Pituitary; 2007;10(3):311-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment.
  • Although clinical improvement is common after treatment with somatostatin (SMS) analogs, the biochemical response and tumor size of the growth hormone-releasing hormone (GHRH)-producing tumor and its metastases are less predictable.
  • Subject A 36-year-old male was referred because of a 3-year history of acromegaly related symptoms.
  • He had undergone lung surgery in 1987 for a "benign" carcinoid tumor.
  • Endocrine evaluation confirmed acromegaly Plasma IGF-1: 984 ng/ml (63-380), GH: 49.8 ng/ml (<5).
  • Methods Measurement of circulating GHRH levels by fluorescence immunoassay levels and immunohistochemical study of the primary lung tumor and metastatic tissue with anti-GHRH and anti-somatostatin receptor type 2 (sst2A) antibodies.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Bronchial Neoplasms / secondary. Bronchial Neoplasms / secretion. Carcinoid Tumor / secondary. Carcinoid Tumor / secretion. Growth Hormone-Releasing Hormone / secretion. Hormones, Ectopic / secretion. Human Growth Hormone / secretion. Octreotide / therapeutic use

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1988 Aug;67(2):395-9 [2899089.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3162-9 [10487681.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] J Clin Invest. 1986 Oct;78(4):906-13 [3093533.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):798-827 [9861546.001]
  • [Cites] Endokrynol Pol. 2006 Jan-Feb;57(1):32-6 [16575760.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jul;57(1):131-4 [12100081.001]
  • [Cites] J Thorac Cardiovasc Surg. 1985 Jun;89(6):819-25 [2582209.001]
  • [Cites] Endocrinol Metab Clin North Am. 1991 Sep;20(3):507-18 [1935918.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Nov;90(11):6156-61 [16091489.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Jun;34(6):463-7 [1653654.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):221-6 [2891432.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1642-51 [16327437.001]
  • [Cites] Neurochirurgia (Stuttg). 1992 Sep;35(5):160-2 [1436366.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):43-54 [6243140.001]
  • [Cites] Endocrinology. 1989 Aug;125(2):801-9 [2502376.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2375-8 [9622077.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2605-13 [15495181.001]
  • [Cites] Eur J Nucl Med. 1998 Jul;25(7):675-86 [9662588.001]
  • [Cites] J Laryngol Otol. 2005 May;119(5):405-8 [15949110.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] J Physiol Paris. 2000 May-Aug;94(3-4):205-10 [11087998.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Ann Thorac Surg. 1996 Sep;62(3):798-809; discussion 809-10 [8784011.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):955-62 [16954443.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):224-31 [15272918.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jul;55(1):135-40 [11453963.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • (PMID = 17373589.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Blood Glucose; 0 / Hormones, Ectopic; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 12629-01-5 / Human Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


8. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A: Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery; 2005 Dec;138(6):1102-9; discussion 1109-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
  • We postulated that expression analysis of genes that modulate angiogenesis would identify differentially expressed genes that would help to distinguish benign from malignant thyroid neoplasms and serve as markers of aggressive differentiated thyroid cancer.
  • METHODS: A complementary DNA (cDNA) array with 96 genes that modulate angiogenesis was used to identify differentially expressed genes (2-fold higher or lower) in malignant versus benign thyroid neoplasms.
  • RESULTS: Twenty-two genes were upregulated in malignant thyroid neoplasms by cDNA array analysis, but only 13 genes had higher messenger RNA (mRNA) expression levels in malignant than in benign thyroid neoplasms by real-time quantitative polymerase chain reaction (P < or = .04).
  • Of the 13 differentially expressed genes, the combined use of angiopoietin 2 (ANGPT2) and tissue inhibitor of metalloproteinase 1 (TIMP1) mRNA expression levels was best for distinguishing malignant from benign thyroid neoplasms, with a sensitivity of 90%, specificity of 85%, positive predictive value of 75%, and negative predictive value of 94%.
  • Epidermal growth factor receptor and ephrin B2 mRNA expression was elevated in higher TNM stage neoplasms and in patients with high-risk AMES (Age, distant Metastasis, Extrathyroidal invasion, and tumor Size) differentiated thyroid cancers (P < or = .005).
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma / genetics. Angiogenic Proteins / genetics. Carcinoma, Papillary / genetics. Carcinoma, Papillary, Follicular / genetics. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics


9. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M: Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer; 2005 Jun;12(2):305-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
  • The distinction of benign from malignant follicular thyroid neoplasms remains a difficult task in diagnostic fine-needle aspiration cytology, and some discrepant results have been reported for the individual immunocytochemical markers of malignancy proposed so far.
  • The aim of this study was to test if the combined use of a panel of markers could improve the diagnostic accuracy in the preoperative cytological evaluation of 'follicular neoplasms' in an attempt to reduce the number of thyroidectomies performed for benign lesions.
  • The immunocytochemical expression of galectin-3, HBME-1, thyroperoxidase, cytokeratin-19 and keratan-sulfate was retrospectively analyzed in 125 consecutive fine-needle aspiration samples (cell blocks) of indeterminate diagnoses of 'follicular thyroid neoplasm', and compared with their corresponding surgical specimens, including 33 follicular carcinomas, 42 papillary carcinomas and 50 follicular adenomas.
  • The use of these two markers sequentially in non-oncocytic lesions (testing HBME-1 as a second marker whenever galectin-3 proved negative) increased the sensitivity and specificity up to 97% and 95% respectively.
  • Our data showed that, as compared with the use of single markers, the sequential combination of two markers represents the most accurate immunohistochemical panel in managing patients with a fine-needle aspiration biopsy diagnosis of 'follicular neoplasms', especially in otherwise controversial categories such as oncocytic tumours.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Biomarkers, Tumor / analysis. Immunohistochemistry. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947105.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Metz DC, Jensen RT: Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology; 2008 Nov;135(5):1469-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.
  • Pancreatic endocrine tumors (PETs) have long fascinated clinicians and investigators despite their relative rarity.
  • Their clinical presentation varies depending on whether the tumor is functional or not, and also according to the specific hormonal syndrome produced.
  • Chromogranin A appears to be the most useful serum marker for diagnosis, staging, and monitoring.
  • Most PETs are relatively indolent but ultimately malignant, except for insulinomas, which predominantly are benign.
  • Surgery is the only modality that offers the possibility of cure, although it generally is noncurative in patients with Zollinger-Ellison syndrome or nonfunctional PETs with multiple endocrine neoplasia-type 1.
  • Systemic or regional therapies generally are reserved until symptoms occur or tumor growth is rapid.
  • This review addresses a number of recent advances regarding the molecular pathology, diagnosis, localization, and management of PETs including discussion of peptide-receptor radionuclide therapy and other novel antitumor approaches.
  • [MeSH-major] Pancreatic Neoplasms
  • [MeSH-minor] Combined Modality Therapy / methods. Diagnosis, Differential. Diagnostic Imaging / methods. Global Health. Humans. Morbidity. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Transpl. 2007 Mar;13(3):327-33 [17318853.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):1118-28 [17179192.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):1-14 [17382262.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):15-31 [17382263.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):33-41 [17382264.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):43-68 [17382265.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):69-85 [17382266.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):87-109 [17382267.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):111-29 [17382268.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):131-44 [17382269.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):145-62 [17382270.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):163-72 [17382271.001]
  • [Cites] J Nucl Med. 2007 Apr;48(4):508-18 [17401086.001]
  • [Cites] Ann Chir. 2000 Feb;125(2):118-23 [10998796.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1425-30 [11038217.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):1087-95 [11040195.001]
  • [Cites] Surgery. 2000 Dec;128(6):903-9 [11114622.001]
  • [Cites] Surgery. 2000 Dec;128(6):1022-7;discussion 1027-8 [11114638.001]
  • [Cites] Medicine (Baltimore). 2000 Nov;79(6):379-411 [11144036.001]
  • [Cites] Dig Dis Sci. 2001 Mar;46(3):610-7 [11318541.001]
  • [Cites] Medicine (Baltimore). 2001 May;80(3):189-222 [11388095.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Aug;11(4):279-83 [11525376.001]
  • [Cites] Arch Surg. 2001 Sep;136(9):1020-5 [11529824.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Oct;15(10):1555-61 [11563994.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):495-505; discussion 505-6 [11573043.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1403-7 [11578300.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1967-73 [17513802.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):675-97 [16253893.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):699-704 [16253894.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):753-81 [16253899.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):783-98 [16253900.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):799-805 [16253901.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):819-30 [16253903.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1508-12 [16231278.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):683-99 [16322317.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1083-92 [16322345.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):138-45 [16368504.001]
  • [Cites] JOP. 2006;7(1):150-6 [16407638.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Feb 1;23(3):437-44 [16423003.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Feb;4(2):148-53 [16451771.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):461-6 [16364959.001]
  • [Cites] Semin Nucl Med. 2006 Apr;36(2):147-56 [16517236.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):572-81 [16511671.001]
  • [Cites] Pancreatology. 2006;6(1-2):155-9 [16354964.001]
  • [Cites] World J Surg. 2006 May;30(5):654-62; discussion 663-4 [16680582.001]
  • [Cites] Anticancer Drugs. 2006 Jun;17(5):487-94 [16702804.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):541-58 [16728581.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):135-9 [16761630.001]
  • [Cites] Adv Exp Med Biol. 2006;574:43-56 [16836240.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3548-54 [16877720.001]
  • [Cites] Endocr Pract. 2006 Jul-Aug;12(4):394-400 [16901794.001]
  • [Cites] Diagn Cytopathol. 2006 Sep;34(9):649-58 [16900463.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2006 Jul;114(7):361-5 [16915538.001]
  • [Cites] Ann Surg. 2006 Sep;244(3):410-9 [16926567.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] World J Surg. 2006 Oct;30(10):1916-9; discussion 1920-1 [16855802.001]
  • [Cites] Pancreas. 2006 Oct;33(3):211-20 [17003640.001]
  • [Cites] World J Gastroenterol. 2006 Sep 14;12(34):5440-6 [17006979.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1000-4; discussion 1005 [17043278.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Nov;22(6):593-8 [17053435.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1148-54 [17031397.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Nov 15;24(10):1439-44 [17081164.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2474-81 [17054107.001]
  • [Cites] Medicine (Baltimore). 2006 Nov;85(6):295-330 [17108778.001]
  • [Cites] Medicine (Baltimore). 2006 Nov;85(6):331-64 [17108779.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1065-73 [16969122.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1195-202 [17158764.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1213-21 [17158766.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):234-40 [17200360.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):13-9 [16798833.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Feb;16(2):219-24 [17243941.001]
  • [Cites] Neuroendocrinology. 2006;84(3):173-82 [17312377.001]
  • [Cites] Neuroendocrinology. 2006;84(3):183-8 [17312378.001]
  • [Cites] Neuroendocrinology. 2006;84(3):196-211 [17312380.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):228-39 [17315031.001]
  • [Cites] Gastroenterology. 1988 Jun;94(6):1326-34 [2966088.001]
  • [Cites] Surgery. 1988 Dec;104(6):1011-7 [2904180.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] Endocrinol Metab Clin North Am. 1989 Mar;18(1):45-74 [2537193.001]
  • [Cites] Dig Dis Sci. 1989 Mar;34(3 Suppl):28S-39S [2537716.001]
  • [Cites] Radiology. 1989 Jun;171(3):713-7 [2655004.001]
  • [Cites] Gastroenterology. 1989 Aug;97(2):468-71 [2663614.001]
  • [Cites] Ann Intern Med. 1989 Nov 1;111(9):713-22 [2572194.001]
  • [Cites] Surgery. 1989 Dec;106(6):1108-17; discussion 1117-8 [2573957.001]
  • [Cites] Radiology. 1990 Jan;174(1):25-9 [2294556.001]
  • [Cites] Gastroenterology. 1990 Feb;98(2):341-6 [1967239.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):365-75; discussion 375-6 [2368440.001]
  • [Cites] AJR Am J Roentgenol. 1990 Sep;155(3):501-5 [1974734.001]
  • [Cites] AJR Am J Roentgenol. 2007 May;188(5):1201-7 [17449759.001]
  • [Cites] Gastroenterology. 1990 Dec;99(6):1622-7 [2227278.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Jun;21(3):561-73; x [17548040.001]
  • [Cites] J Obstet Gynaecol Res. 2007 Jun;33(3):392-6 [17578375.001]
  • [Cites] Curr Top Med Chem. 2007;7(12):1211-31 [17584143.001]
  • [Cites] Expert Opin Emerg Drugs. 2007 May;12(2):253-70 [17604500.001]
  • [Cites] Eur J Endocrinol. 2007 Jul;157(1):75-83 [17609405.001]
  • [Cites] Cancer Control. 2007 Jul;14(3):295-304 [17615536.001]
  • [Cites] Surgery. 2007 Jul;142(1):10-9 [17629995.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):473-82 [17639060.001]
  • [Cites] Acta Oncol. 2007;46(6):723-34 [17653893.001]
  • [Cites] Neuroendocrinology. 2007;85(4):216-20 [17541257.001]
  • [Cites] J Gastroenterol. 2007 Jun;42(6):497-500 [17671766.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):515-21 [17762557.001]
  • [Cites] Med Oncol. 2007;24(3):330-7 [17873310.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] J Gastrointestin Liver Dis. 2007 Sep;16(3):295-6 [17925925.001]
  • [Cites] Yale J Biol Med. 2006 Dec;79(3-4):105-14 [17940620.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1331-41 [17939142.001]
  • [Cites] Am Surg. 2007 Oct;73(10):941-4 [17983052.001]
  • [Cites] Am J Gastroenterol. 2007 Dec;102(12):2648-54 [17764495.001]
  • [Cites] Surgery. 2007 Dec;142(6):814-8; discussion 818.e1-2 [18063061.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):165-72 [18156937.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):382-93 [17510774.001]
  • [Cites] Ann Surg. 2008 Mar;247(3):501-10 [18376196.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Apr;23(4):521-6 [17645474.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1582-91 [18270260.001]
  • [Cites] Cancer. 2008 Oct 1;113(7 Suppl):1807-43 [18798544.001]
  • [Cites] Pituitary. 2006;9(3):221-9 [17036195.001]
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3392-400 [15755858.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1259-65 [16001675.001]
  • [Cites] Diagn Cytopathol. 2005 Aug;33(2):100-5 [16007666.001]
  • [Cites] Abdom Imaging. 2005 Jul-Aug;30(4):435-41 [15759207.001]
  • [Cites] Abdom Imaging. 2005 Jul-Aug;30(4):427-34 [15791486.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):507-17 [16183524.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):519-34 [16183525.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):535-51 [16183526.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):577-83 [16183528.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):585-94 [16183529.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):617-36 [16183531.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):637-48 [16183532.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):649-56 [16183533.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1590-602 [16134179.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):116-23 [10634374.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):696-704 [10734021.001]
  • [Cites] Acta Radiol. 2000 Mar;41(2):172-7 [10741793.001]
  • [Cites] Pathol Int. 2000 Feb;50(2):146-52 [10792774.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):419-25 [10989643.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Jan;12(1):83-98 [9692706.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):77-85 [9683758.001]
  • [Cites] Ann Surg. 1998 Aug;228(2):228-38 [9712569.001]
  • [Cites] Transplantation. 1998 Nov 27;66(10):1307-12 [9846513.001]
  • [Cites] Surgery. 1998 Dec;124(6):1145-52 [9854596.001]
  • [Cites] Surgery. 1998 Dec;124(6):1153-9 [9854597.001]
  • [Cites] Gut. 1998 Sep;43(3):422-7 [9863490.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):312-9 [9880781.001]
  • [Cites] Eur J Clin Invest. 1998 Dec;28(12):1038-49 [9893017.001]
  • [Cites] Curr Opin Oncol. 1999 Jan;11(1):38-41 [9914876.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):615-30 [10080607.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Dec;17(4):379-88 [10089055.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Dec;17(4):389-400 [10089056.001]
  • [Cites] Virchows Arch. 2002 May;440(5):461-75 [12021920.001]
  • [Cites] Am J Med. 1999 Mar;106(3):307-10 [10190379.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):68-85 [12105835.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2273-85 [12114431.001]
  • [Cites] Curr Pharm Des. 2002;8(20):1781-807 [12171531.001]
  • [Cites] Dig Liver Dis. 2002 Sep;34(9):668-80 [12405256.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):855-62 [12417506.001]
  • [Cites] Eur J Pediatr. 2002 Nov;161(11):600-3 [12424585.001]
  • [Cites] Radiology. 2002 Dec;225(3):751-8 [12461257.001]
  • [Cites] J Nucl Med. 2003 Mar;44(3):359-68 [12621001.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1469-73 [12684421.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):231-42 [12735141.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):29-37 [12831921.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2689-96 [12860945.001]
  • [Cites] Endocr Pract. 2003 Jan-Feb;9(1):22-5 [12917088.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):145-51 [12946485.001]
  • [Cites] Gastrointest Endosc. 2003 Oct;58(4):531-5 [14520285.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1766-75 [14583782.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):413-9 [14585087.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5353-60 [14602773.001]
  • [Cites] Drugs. 2003;63(22):2473-99 [14609359.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2435-9 [14638345.001]
  • [Cites] Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5 [14668741.001]
  • [Cites] J Endocrinol Invest. 2003 Aug;26(8):758-61 [14669832.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5988-95 [14676124.001]
  • [Cites] Medicine (Baltimore). 2004 Jan;83(1):43-83 [14747767.001]
  • [Cites] Dig Liver Dis. 2004 Feb;36 Suppl 1:S106-20 [15077919.001]
  • [Cites] Ann Surg. 2004 May;239(5):617-25; discussion 626 [15082965.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:199-208 [15153435.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2240-2 [15169813.001]
  • [Cites] Endocr Rev. 2004 Jun;25(3):458-511 [15180952.001]
  • [Cites] J Endocrinol Invest. 2004 Apr;27(4):361-5 [15233557.001]
  • [Cites] Pancreatology. 2004;4(5):417-33; discussion 434-5 [15249710.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6152-8 [15448002.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:35-8 [15477715.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):757-73 [15492556.001]
  • [Cites] N Engl J Med. 1979 Aug 9;301(6):285-92 [377080.001]
  • [Cites] N Engl J Med. 1980 Nov 20;303(21):1189-94 [6252466.001]
  • [Cites] Gastroenterology. 1980 Dec;79(6):1324-31 [7439637.001]
  • [Cites] Am J Surg. 1980 May;139(5):682-90 [6258453.001]
  • [Cites] Ann Surg. 1981 Dec;194(6):671-6 [7305478.001]
  • [Cites] J Endocrinol Invest. 1981 Oct-Dec;4(4):451-3 [6120969.001]
  • [Cites] Gastroenterology. 1983 Jan;84(1):108-13 [6128284.001]
  • [Cites] AJR Am J Roentgenol. 1984 Sep;143(3):585-9 [6087646.001]
  • [Cites] Ann Surg. 1986 Apr;203(4):352-9 [2938550.001]
  • [Cites] N Engl J Med. 1986 Jul 3;315(1):1-5 [2872593.001]
  • [Cites] Scand J Gastroenterol Suppl. 1986;119:54-64 [2876507.001]
  • [Cites] Ann Surg. 1986 Oct;204(4):468-79 [3532971.001]
  • [Cites] Surgery. 1987 Dec;102(6):958-66 [2891201.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):294-9 [3335308.001]
  • [Cites] Gastroenterology. 1990 Oct;99(4):943-50 [1697548.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Radiology. 1992 Jan;182(1):235-41 [1727289.001]
  • [Cites] Surgery. 1991 Dec;110(6):1086-91; discussion 1091-3 [1745977.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):8-18 [1531004.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):519-23 [1310159.001]
  • [Cites] Ann Surg. 1992 Jun;215(6):561-9; discussion 569-70 [1352963.001]
  • [Cites] Gastroenterology. 1992 Nov;103(5):1498-508 [1426868.001]
  • [Cites] Gut. 1992 Sep;33(9):1275-9 [1358767.001]
  • [Cites] Surgery. 1992 Dec;112(6):1002-8; discussion 1008-9 [1455303.001]
  • [Cites] Surgery. 1992 Dec;112(6):1024-31; discussion 1031-2 [1455305.001]
  • [Cites] Dig Dis Sci. 1993 Feb;38(2):245-56 [8425437.001]
  • [Cites] Pancreas. 1993 May;8(3):295-304 [8097874.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):199-206 [8323088.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):138-44 [8342993.001]
  • [Cites] Eur J Nucl Med. 1993 Aug;20(8):716-31 [8404961.001]
  • [Cites] Aliment Pharmacol Ther. 1993 Dec;7(6):597-610 [8161665.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):320-8; discussion 328-30 [7916560.001]
  • [Cites] Am J Med. 1994 Nov;97(5):436-44 [7977432.001]
  • [Cites] Ann N Y Acad Sci. 1994 Sep 15;733:488-95 [7978899.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1637-49 [7768367.001]
  • [Cites] Semin Gastrointest Dis. 1995 Apr;6(2):90-101 [7788287.001]
  • [Cites] Ann Intern Med. 1995 Aug 15;123(4):269-73 [7611592.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2768-75 [7673422.001]
  • [Cites] Surgery. 1995 Dec;118(6):973-9; discussion 979-80 [7491542.001]
  • [Cites] Radiology. 1996 Jan;198(1):77-84 [8539410.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):26-34 [8644985.001]
  • [Cites] Gut. 1996 Mar;38(3):430-8 [8675099.001]
  • [Cites] Endoscopy. 1996 Mar;28(3):273-6 [8781789.001]
  • [Cites] World J Surg. 1996 Sep;20(7):878-83; discussion 884 [8678966.001]
  • [Cites] Aliment Pharmacol Ther. 1996 Feb;10(1):61-71 [8871445.001]
  • [Cites] Gut. 1996 Oct;39(4):562-8 [8944566.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):323-33 [8982376.001]
  • [Cites] Radiology. 1997 Jan;202(1):151-8 [8988205.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):335-47 [9024287.001]
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] Ann Surg. 1997 Apr;225(4):355-64 [9114793.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2238-43 [9187127.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):853-8 [9189129.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2420-31 [9196158.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2622-8 [9253344.001]
  • [Cites] Gut. 1997 Jul;41(1):107-14 [9274481.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Aug;47(2):123-35 [9302383.001]
  • [Cites] World J Surg. 1998 Mar;22(3):309-18 [9494425.001]
  • [Cites] Postgrad Med J. 1997 Oct;73(864):640-1 [9497974.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1040-53 [9508189.001]
  • [Cites] Abdom Imaging. 1998 May-Jun;23(3):322-31 [9569307.001]
  • [Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 2):866-73 [9591806.001]
  • [Cites] Am J Med. 1998 May;104(5):422-30 [9626024.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):477-88 [9681846.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):489-94 [9681847.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:182-4 [10436817.001]
  • [Cites] N Engl J Med. 1999 Aug 26;341(9):635-44 [10460814.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):944-8 [10491519.001]
  • [Cites] FASEB J. 1999 Oct;13(13):1658-76 [10506570.001]
  • [Cites] J Nucl Med. 1999 Oct;40(10):1602-8 [10520698.001]
  • [Cites] Am J Med. 1954 Mar;16(3):363-71 [13138607.001]
  • [Cites] Curr Gastroenterol Rep. 2004 Dec;6(6):454-63 [15527675.001]
  • [Cites] Eur J Endocrinol. 2004 Nov;151(5):531-7 [15538929.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4762-71 [15570077.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1317-22 [15517479.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):689-708 [15613446.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jan;3(1):39-48 [15645403.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:62S-6S [15653653.001]
  • [Cites] Gastroenterol Clin Biol. 2004 Nov;28(11):1075-81 [15657529.001]
  • [Cites] Mol Cancer. 2005 Feb 3;4(1):9 [15691381.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2005 Jun;19(2):177-93 [15763694.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2005 Jun;19(2):195-211 [15763695.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2005 Jun;19(2):213-27 [15763696.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2005 Jun;19(2):229-39 [15763697.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2005 Jun;19(2):311-24 [15763703.001]
  • [Cites] Langenbecks Arch Surg. 2005 Apr;390(2):134-40 [15609056.001]
  • [Cites] Mayo Clin Proc. 2005 Apr;80(4):502-6 [15819288.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2754-62 [15837990.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3233-42 [15867218.001]
  • [Cites] Eur J Endocrinol. 2005 May;152(5):757-67 [15879362.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Curr Cancer Drug Targets. 2005 May;5(3):171-93 [15892618.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:74-8 [15477722.001]
  • [Cites] Eur J Ultrasound. 1999 Nov;10(2-3):139-50 [10586018.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S186-9 [10604127.001]
  • (PMID = 18703061.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 DK053200-16; United States / Intramural NIH HHS / / Z01 DK053215-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 308
  • [Other-IDs] NLM/ NIHMS78368; NLM/ PMC2612755
  •  go-up   go-down


11. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P: Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer; 2008 Mar;15(1):337-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
  • Gastric endocrine tumors associated with autoimmune chronic atrophic gastritis (gastric carcinoid type I) are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall.
  • Nine patients with more than five type I gastric endocrine tumors each <1 cm in size, without invasion of the muscularis propria and with Ki-67 index lower than 3%, were treated with long-acting somatostatin analogs for 12 months.
  • This therapeutic approach should be considered as a valid option in selected patients with multiple type I gastric endocrine tumors.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / drug therapy. Gastritis, Atrophic / drug therapy. Octreotide / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310299.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Chromogranin A; 0 / Gastrins; RWM8CCW8GP / Octreotide
  •  go-up   go-down


12. Nord KH, Magnusson L, Isaksson M, Nilsson J, Lilljebjörn H, Domanski HA, Kindblom LG, Mandahl N, Mertens F: Concomitant deletions of tumor suppressor genes MEN1 and AIP are essential for the pathogenesis of the brown fat tumor hibernoma. Proc Natl Acad Sci U S A; 2010 Dec 7;107(49):21122-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant deletions of tumor suppressor genes MEN1 and AIP are essential for the pathogenesis of the brown fat tumor hibernoma.
  • Hibernomas are benign tumors with morphological features resembling brown fat.
  • Here we demonstrate that these aberrations are associated with concomitant deletions of AIP and MEN1, tumor suppressor genes that are located 3 Mb apart and that underlie the hereditary syndromes pituitary adenoma predisposition and multiple endocrine neoplasia type I.
  • Simultaneous loss of two tumor suppressor genes has not previously been shown to result from a neoplasia-associated translocation.
  • Furthermore, in contrast to the prevailing assumption that benign tumors harbor relatively few genetic aberrations, the present analyses demonstrate that a considerable number of chromosome breaks are involved in the pathogenesis of hibernoma.
  • [MeSH-major] Gene Deletion. Genes, Tumor Suppressor. Intracellular Signaling Peptides and Proteins / genetics. Lipoma / genetics. Multiple Endocrine Neoplasia Type 1 / genetics


13. Dong Y, Bui LT, Odorico DM, Tan OL, Myers SA, Samaratunga H, Gardiner RA, Clements JA: Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. Endocr Relat Cancer; 2005 Dec;12(4):875-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prostate-specific antigen-related serine protease gene, kallikrein 4 (KLK4), is expressed in the prostate and, more importantly, overexpressed in prostate cancer.
  • Using V5/His6 and green fluorescent protein (GFP) carboxy terminal tagged expression constructs and immunocytochemical approaches, we found that hK4-254 is cytoplasmically localized, while the N-terminal truncated hK4-205 is in the nucleus of transfected PC-3 prostate cancer cells.
  • At the protein level, using anti-hK4 peptide antibodies specific to different regions of hK4-254 (N-terminal and C-terminal), we also demonstrated that endogenous hK4-254 (detected with the N-terminal antibody) is more intensely stained in malignant cells than in benign prostate cells, and is secreted into seminal fluid.
  • In contrast, for the endogenous nuclear-localized N-terminal truncated hK4-205 form, there was less difference in staining intensity between benign and cancer glands.
  • [MeSH-major] Cell Nucleus / chemistry. Cytoplasm / chemistry. Kallikreins / analysis. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Androgens / metabolism. Cell Line, Tumor. Glycosylation. Humans. Male. Protein Biosynthesis. Protein Isoforms / analysis. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA, Messenger / analysis. RNA, Messenger / metabolism. Semen / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322328.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / Protein Isoforms; 0 / RNA, Messenger; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4; EC 3.4.21.77 / KLK4-205, human
  •  go-up   go-down


1
Advertisement
4. Müller HL, Handwerker G, Gebhardt U, Faldum A, Emser A, Kolb R, Sörensen N: Melatonin treatment in obese patients with childhood craniopharyngioma and increased daytime sleepiness. Cancer Causes Control; 2006 May;17(4):583-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngioma is a rare dysontogenetic benign tumor.
  • Patients frequently suffer from endocrine deficiencies, sleep disturbances and obesity due to pituitary and hypothalamic lesions.
  • Because hypothalamic lesions may explain daytime sleepiness in craniopharyngioma patients, salivary melatonin and cortisol concentrations were examined in severely obese (BMI>or=4SD) and non severely obese (BMI<4SD) craniopharyngioma patients (n=79), patients with hypothalamic pilocytic astrocytoma (n=19), and control subjects (n=30).
  • Using a general linear model procedure analyzing the influence of BMI and tumor diagnosis on diurnal salivary melatonin we found that morning salivary melatonin levels were related to BMI (F test: p-value=0.004) and tumor diagnosis (F-test: p-value=0.032).
  • Also for nighttime salivary melatonin levels significant relations with BMI (p-value in F-test: <0.001) and tumor diagnosis (p-value in F-test: 0.025) were detectable.
  • Severely obese craniopharyngioma patients and severely obese hypothalamic tumor patients had similar patterns of melatonin secretion.
  • As decreased nocturnal melatonin levels were associated with increased daytime sleepiness, BMI and hypothalamic tumor diagnosis, we initiated an experimental melatonin substitution in 10 adult obese patients (5f/5m) with childhood craniopharyngioma.
  • [MeSH-major] Craniopharyngioma / metabolism. Melatonin / secretion. Melatonin / therapeutic use. Obesity / metabolism. Pituitary Neoplasms / metabolism. Sleep Stages
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / complications. Astrocytoma / metabolism. Child. Child, Preschool. Circadian Rhythm. Disorders of Excessive Somnolence / complications. Disorders of Excessive Somnolence / drug therapy. Female. Humans. Hydrocortisone / blood. Hypothalamic Neoplasms / metabolism. Male. Saliva / chemistry


15. Foukakis T, Gusnanto A, Au AY, Höög A, Lui WO, Larsson C, Wallin G, Zedenius J: A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocr Relat Cancer; 2007 Jun;14(2):381-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of follicular thyroid carcinoma (FTC) in the absence of metastasis can only be established postoperatively.
  • Moreover, high-risk FTCs are often not identifiable at the time of diagnosis.
  • The metastatic potential could be predicted in all four cases with apparently benign or minimally invasive (MI) disease at the time of diagnosis, but poor long-term outcome.
  • In addition, a second model was produced by implementing two genes (TERT and TFF3), which was able to distinguish adenomas from de facto carcinomas.
  • When this model was tested in an independent series of atypical adenomas (AFTA) and MI-FTCs, 16 out of 17 AFTAs were classified as 'benign', while MI-FTCs with vascular invasion (sometimes referred to as 'moderately invasive') and/or large tumor size tended to classify in the 'malignant' group.
  • The reported models can be the foundation for the development of reliable preoperative diagnostic and prognostic tests that can guide the therapeutic approach of follicular thyroid neoplasms with indeterminate cytology.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Gene Expression. Genes, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639052.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


16. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M: Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol; 2008 May;19(5):903-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.
  • BACKGROUND: Non-functioning pancreatic endocrine tumours (NF-PETs) are an aggressive gastroenteropancreatic neoplasm.
  • The present study assessed survival, value of World Health Organisation (WHO) classification and prognostic utility of clinicopathological parameters at diagnosis.
  • RESULTS: There were 25 (14%) benign lesions, 38 (21%) neoplasms of uncertain behaviour, 100 well-differentiated carcinomas (56%) and 17 poorly differentiated carcinomas (9%).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209014.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


17. Langer P, Bartsch DK, Fendrich V, Kann PH, Rothmund M, Zielke A: [Minimal-invasive operative treatment of organic hyperinsulinism]. Dtsch Med Wochenschr; 2005 Mar 11;130(10):514-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Insulinomas are small, solitary and benign endocrine pancreatic tumours, causing organic hyperinsulinism by autonomous insulin-secretion.
  • Conventional imaging procedures were non diagnostic whereas endoscopic ultrasound of the pancreas revealed a 8 x 13 and 10 x 9 mm lesion in the pancreas.
  • THERAPY AND COURSE: Laparoscopic resection of the tumor was attempted and accomplished in both patients.
  • The young man underwent laparoscopic enucleation of the tumor, while the 50 year old man underwent left sided laparoscopic resection of the pancreas because the tumor was adjacent to the pancreatic duct.
  • [MeSH-minor] Adolescent. Endosonography. Humans. Insulinoma / complications. Insulinoma / surgery. Insulinoma / ultrasonography. Male. Middle Aged. Pancreas / pathology. Pancreas / surgery. Pancreas / ultrasonography. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / ultrasonography

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744643.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Kapran Y, Bauersfeld J, Anlauf M, Sipos B, Klöppel G: Multihormonality and entrapment of islets in pancreatic endocrine tumors. Virchows Arch; 2006 Apr;448(4):394-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multihormonality and entrapment of islets in pancreatic endocrine tumors.
  • We analyzed pancreatic endocrine tumors (PETs) from 200 patients for the incidence of multihormonality and entrapped islets and correlated the results with clinicopathological features.
  • Classified according to the WHO classification, there were 32 well-differentiated benign PETs, 85 well-differentiated PETs with uncertain behavior, and 83 well-differentiated malignant PETs.
  • Islet entrapment was found in 57 tumors (28.5%) and was significantly more frequent in PETs with uncertain and malignant behavior than benign ones (p=0.01).
  • We conclude that the incidence of multihormonality in PETs is not as high as suggested previously and islet entrapping may reflect aggressive tumor growth and may be a complementary criterion for predicting the biological behavior of PETs.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / pathology. Islets of Langerhans / pathology. Pancreatic Hormones / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Count. Child. Child, Preschool. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):104-8 [10839610.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):191-8 [1317556.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1420-9 [2992737.001]
  • [Cites] Semin Diagn Pathol. 1984 Nov;1(4):285-96 [6100974.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):908-15 [6277456.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):323-33 [8982376.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):813-20 [15166675.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):258-65 [12647216.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):461-8 [12657930.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Hum Pathol. 1982 Mar;13(3):263-71 [7076209.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1378-84 [8898842.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] Surg Today. 1992;22(4):305-12 [1392340.001]
  • [Cites] Histopathology. 1978 Nov;2(6):389-99 [215502.001]
  • [Cites] Am J Surg Pathol. 1982 Jul;6(5):387-99 [6127037.001]
  • [Cites] Histopathology. 2002 Aug;41(2):122-6 [12147089.001]
  • [Cites] Am J Pathol. 1975 May;79(2):271-84 [167586.001]
  • [Cites] Virchows Arch. 2003 May;442(5):444-52 [12692724.001]
  • (PMID = 16418841.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pancreatic Hormones
  •  go-up   go-down


19. Clemente G, Sarno G, Giordano M, De Rose AM, Giovannini I, Vecchio FM, Nuzzo G: Total gastrectomy for type 1 gastric carcinoid: an unusual surgical indication? Minerva Chir; 2007 Oct;62(5):421-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric carcinoid is a relatively rare neoplasm with peculiar features which differentiate it from the intestinal and pulmonary carcinoid and, obviously, from gastric adenocarcinoma.
  • Gastric carcinoids are divided into three different types: Type 1, associated with gastric atrophy and megaloblastic anemia; Type 2, associated with Zollinger-Ellison syndrome within a type 1 multiple endocrine neoplasia (MEN); and Type 3, sporadic tumor not associated with other lesions, particularly invasive and with poor prognosis.
  • It is generally small, multifocal and located in the gastric fundus, has no tendency for vascular invasion and is associated with a benign course.
  • We report a case of a woman with a type 1 gastric carcinoid in which, for the presence of an extended micro-polyposis of the fundus a total gastrectomy was necessary for treatment.
  • [MeSH-major] Carcinoid Tumor / surgery. Gastrectomy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947953.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Ketari-Jamoussi S, Debbiche-Chedly A, Ben Dhaou B, Boussema F, Cherif O, Cherif AR, Ben Ayed M, Bouzaine A, Rokbani L: [Giant insulinoma]. Ann Endocrinol (Paris); 2009 Mar;70(1):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Islet-cell tumors are the most common neuroendocrine tumors that arise from the endocrine pancreas.
  • They are typically benign and sporadic.
  • Diagnosis is generally established late because clinical signs lack specificity.
  • Imaging studies showed a voluminous tumor located between the pancreas and the spleen.
  • Histopathological examination revealed a malignant, well-differentiated neuroendocrine malignant tumor.
  • [MeSH-major] Insulinoma / pathology. Insulinoma / surgery. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937931.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 9035-68-1 / Proinsulin
  •  go-up   go-down


21. Rubin MR, Bilezikian JP, Birken S, Silverberg SJ: Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur J Endocrinol; 2008 Oct;159(4):469-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Preoperatively, it is difficult to differentiate between parathyroid cancer (PtCa) and severe primary hyperparathyroidism (PHPT) due to a benign tumor.
  • Human chorionic gonadotropin (hCG) is a tumor marker in trophoblastic and nontrophoblastic cancers and hyperglycosylated hCG is increased in hCG-secreting malignancies.
  • We investigated whether hCG can distinguish PtCa cancer from benign disease and add prognostic information.
  • RESULTS: Total urinary hCG was normal in the benign PHPT control subjects (range: 0-17 fmol/mg Cr; nl<50).
  • Serum malignant hyperglycosylated hCG values in all of the cancer patients exceeded the maximal serum malignant hCG level of the PHPT subjects with benign disease (3.77 pmol/l).
  • Further studies would help to elucidate the role of hCG as a potential tumor marker in this disease.

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Exp Pathol. 1987 Dec;68(6):871-8 [2447930.001]
  • [Cites] Cancer Lett. 1991 Jun 14;58(1-2):145-50 [1646686.001]
  • [Cites] World J Surg. 1991 Nov-Dec;15(6):738-44 [1767540.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1829-42 [1372528.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4628-33 [1324787.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(6):461-6 [1282101.001]
  • [Cites] Endocrinology. 1994 Mar;134(3):1139-45 [7509735.001]
  • [Cites] Eur J Clin Invest. 1994 Feb;24(2):131-6 [7515807.001]
  • [Cites] J Pathol. 1998 Aug;185(4):389-93 [9828837.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):757-62 [10091751.001]
  • [Cites] J Endocrinol. 1999 Apr;161(1):99-106 [10194533.001]
  • [Cites] Endocrine. 1999 Apr;10(2):137-44 [10451222.001]
  • [Cites] Tumour Biol. 2005 May-Jun;26(3):131-41 [15970647.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4803-7 [17214344.001]
  • [Cites] Cancer. 2007 May 1;109(9):1736-41 [17372919.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3803-8 [17666472.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1553-6 [10789723.001]
  • [Cites] Clin Chem. 2003 May;49(5):808-10 [12709375.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):144-54 [12507971.001]
  • [Cites] J Endocrinol. 2002 Mar;172(3):497-506 [11874698.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):485-93 [11157996.001]
  • [Cites] Br J Cancer. 2002 Jan 21;86(2):185-9 [11870503.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1254-9 [12748494.001]
  • [Cites] J Urol. 1987 Mar;137(3):502-4 [3820387.001]
  • [Cites] Am J Surg. 1985 Apr;149(4):522-7 [3985291.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Jan;54(1):57-63 [6274898.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):549-61 [15234236.001]
  • [Cites] Ann Intern Med. 1973 Jan;78(1):39-45 [4734160.001]
  • (PMID = 18625691.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK074457-03; United States / NIDDK NIH HHS / DK / K24 DK074457; United States / NIDDK NIH HHS / DK / DK32333; United States / NCI NIH HHS / CA / R21 CA 98350; United States / NIDDK NIH HHS / DK / DK074457; United States / NIDDK NIH HHS / DK / K24 DK074457-03; United States / NCI NIH HHS / CA / R21 CA098350; United States / NIDDK NIH HHS / DK / R01 DK032333
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin; 0 / Naphthalenes; 0 / Parathyroid Hormone; 1K860WSG25 / Cinacalcet Hydrochloride; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS247354; NLM/ PMC2970867
  •  go-up   go-down


22. Valente TO, Bertevello PL, Waitzberg DL, Gama-Rodrigues J: [Laparoscopic surgical treatment of insulinomas with the use of intraoperative ultrasonography]. Arq Gastroenterol; 2007 Jan-Mar;44(1):22-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tratamento cirúrgico videolaparoscópico de insulinomas utilizando ultra-sonografia intra-operatória.
  • It is more prevalent between the 5th and 6th decade, in women (2:1) and from the endocrine pancreatic tumor is the more frequent (50% to 60%).
  • Insulinoma behave as a benign tumor when the diameter is inferior to 2 cm.
  • The diagnosis is mainly clinical and laboratorial.
  • RESULTS: The patients had a complete remission of tumor related hypoglycemia and one patient developed a pancreatic fistula and other a pancreatic pseudocist with good postoperative resolution.
  • [MeSH-major] Insulinoma / surgery. Laparoscopy / methods. Pancreatic Neoplasms / surgery. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639178.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


23. Polamaung W, Wisedopas N, Vasinanukorn P, Pak-art P, Snabboon T: Asymptomatic bilateral giant adrenal myelolipomas: case report and review of literature. Endocr Pract; 2007 Oct;13(6):667-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Myelolipoma is a relatively rare benign tumor of the adrenal glands composed of adipose cells and mature hematopoietic elements.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Myelolipoma / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954426.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


24. Schittenhelm J, Ebner FH, Harter P, Bornemann A: Symptomatic intraspinal oncocytic adrenocortical adenoma. Endocr Pathol; 2009;20(1):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most intraspinal neoplasms of epithelial origin are metastases from primary carcinomas.
  • Benign epithelial tumors are rarely found at this site.
  • We here present the case of a 44-year-old woman with a lesion in the cauda equina that fulfilled the radiologic criteria of schwannoma and caused clinical symptoms for 3 years.
  • The excised tumor was composed of nests of large polygonal cells with eosinophilic partial granular cytoplasm.
  • The tumor showed diffuse positivity for melan-A, synaptophysin, and alpha-inhibin.
  • Ultrastructural examination showed abundant mitochondria, suggesting an oncocytic tumor.
  • The diagnosis of an oncocytic adrenal cortical adenoma was made.
  • Oncocytic tumors are rare neoplasms and they comprise non-functioning variants of adrenal cortical adenomas.
  • Immunohistochemistry excluded oncocytic paraganglioma, oncocytic meningioma, renal cell carcinoma, alveolar soft part sarcoma, and granular cell tumor.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenocortical Adenoma / pathology. Spinal Cord Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 2005 Sep;60(9):953-9 [16124976.001]
  • [Cites] Pediatr Neurosurg. 2002 May;36(5):260-5 [12053045.001]
  • [Cites] Spinal Cord. 2007 Feb;45(2):183-6 [16505829.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):57-63 [9422316.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):259-64 [15306940.001]
  • [Cites] J Neurosurg. 2001 Apr;94(2 Suppl):310-2 [11302638.001]
  • [Cites] J Pediatr Surg. 1980 Jun;15(3):289-92 [6103925.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):E1144; discussion E1144 [17143207.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):658-61; discussion 661-2 [8474656.001]
  • [Cites] Histopathology. 1997 Aug;31(2):167-73 [9279569.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):375-82 [9130983.001]
  • [Cites] J Med Case Rep. 2008 Jul 13;2:228 [18620603.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):481-4 [2327553.001]
  • [Cites] Histopathology. 1986 Mar;10(3):311-9 [2422107.001]
  • [Cites] Fetal Pediatr Pathol. 2006 Jul-Aug;25(4):191-7 [17162526.001]
  • [Cites] J Clin Pathol. 1998 Feb;51(2):114-6 [9602683.001]
  • [Cites] AMA Arch Pathol. 1959 Feb;67(2):228-33 [13616833.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):756-9 [10981764.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • (PMID = 19039533.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Casadei R, Ricci C, Rega D, D'Ambra M, Pezzilli R, Tomassetti P, Campana D, Nori F, Minni F: Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. Pancreas; 2010 Aug;39(6):825-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience.
  • OBJECTIVE: Pancreatic endocrine tumors (PETs) are usually small, benign or low-grade malignant, and surgery should preserve the pancreatic parenchyma as much as possible.
  • METHODS: Of 82 patients having PETs, 46 with tumor less than 4 cm in diameter, without distant metastases and with R0 resection by final pathologic examination, were included in this study.
  • Enucleation was performed when the tumor did not involve the main pancreatic duct and in the absence of peripancreatic lymphadenopathy (group A); a typical resection was carried out in all other cases (group B).
  • Postoperative and long-term results were similar in the 2 groups, whereas World Health Organization classification was significantly different; enucleation was performed more frequently than typical R0 resection in benign tumors (P = 0.009).
  • CONCLUSIONS: Enucleation should be reserved for patients having benign PETs less than 4 cm in diameter and far from the main pancreatic duct.
  • [MeSH-major] Neuroendocrine Tumors / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome. World Health Organization

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431423.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Korpershoek E, Stobbe CK, van Nederveen FH, de Krijger RR, Dinjens WN: Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas. Endocr Relat Cancer; 2010 Sep;17(3):653-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas.
  • Pheochromocytomas (PCCs) and extra-adrenal sympathetic paragangliomas (sPGLs) are catecholamine-producing tumors occurring in the context of hereditary tumor syndromes, with known germline mutations, and as sporadic tumors.
  • Since knowledge on intra-tumoral heterogeneity is important for understanding the pathogenesis of these tumors, we investigated 12 benign and 8 malignant PCCs and sPGLs for loss of heterozygosity (LOH) on DNA extracted from different regions of each tumor and from metastases.
  • Benign tumors were found to have less intra-tumoral heterogeneity (overall 8%) than malignant tumors (overall 23%), with the highest frequencies for chromosome 1p36 in the benign tumors (17%) and 1p13 and 3q24 in malignant tumors (both 38%).
  • In addition, differences in LOH patterns were detected between paired primary malignant tumors, and their metastases and different LOH patterns were observed in bilateral PCC of a multiple endocrine neoplasia type 2 patient.
  • We demonstrate that malignant PCC and sPGL have more intra-tumoral molecular heterogeneity than benign tumors, which suggests that benign and malignant PCC and sPGL have a different pathogenesis.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Chromosomes, Human. Loss of Heterozygosity. Paraganglioma / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. DNA, Neoplasm / genetics. Female. Genetic Variation. Histocytochemistry. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20488782.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


27. Savin S, Cvejic D, Isic T, Petrovic I, Paunovic I, Tatic S, Havelka M: Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors. Endocr Pathol; 2006;17(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors.
  • Initial immunohistochemical studies claimed that TPO expression, detected by the monoclonal antibody mAb 47, may be a potentially important diagnostic tool in differentiating malignant from benign lesions.
  • We found that TPO had a sensitivity of 89.9% for cancer and a specificity of 64.4% for nonmalignant lesions, showing that it does not give a sufficient degree of diagnostic certainty that the lesion is benign.
  • In addition, the variability in the degree of TPO expression found within and between follicular carcinomas, and the significant number of benign adenomas having similar immunostaining patterns, assured us that TPO immunostaining is not sufficiently discriminatory in the differential diagnosis of thyroid cancer versus benign lesions.
  • [MeSH-major] Adenoma / enzymology. Carcinoma / enzymology. Iodide Peroxidase / metabolism. Thyroid Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Immunoenzyme Techniques. Retrospective Studies. Sensitivity and Specificity. Thyroid Diseases / diagnosis. Thyroid Diseases / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cesk Patol. 2004 Jan;40(1):18-21 [15035056.001]
  • [Cites] Endocr Pathol. 1998 Winter;9(1):333-338 [12114781.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):875-80 [11556840.001]
  • [Cites] J Pathol. 1996 May;179(1):89-94 [8691351.001]
  • [Cites] Cancer Detect Prev. 1996;20(4):285-93 [8818388.001]
  • [Cites] Endocr J. 1996 Feb;43(1):53-60 [8732452.001]
  • [Cites] Pathol Res Pract. 1997;193(10):705-12 [9505263.001]
  • [Cites] J Clin Endocrinol Metab. 1978 May;46(5):791-9 [262767.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 14;174(3):1148-53 [1996981.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3793-800 [12454013.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):529-34 [7725740.001]
  • [Cites] Eur J Endocrinol. 1994 Nov;131(5):474-9 [7952158.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2478-82 [7852309.001]
  • [Cites] Surgery. 1994 Dec;116(6):1031-5 [7985083.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):871-5 [12820316.001]
  • [Cites] Endocr Pathol. 1999 Autumn;10(3):223-228 [12114702.001]
  • [Cites] Acta Pathol Jpn. 1987 Mar;37(3):425-30 [3618217.001]
  • [Cites] Endocrinol Jpn. 1981 Aug;28(4):381-9 [6305643.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1329-34 [8067701.001]
  • [Cites] Am J Surg. 1990 Sep;160(3):271-6 [2393055.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3036-41 [1710535.001]
  • [Cites] Exp Clin Endocrinol. 1992;100(1-2):51-6 [1281780.001]
  • [Cites] Biochemistry. 2001 Feb 27;40(8):2572-9 [11327880.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Aug;53(2):161-9 [10931096.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 28;1689(2):134-41 [15196594.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Nov;45(5):1089-96 [925133.001]
  • [Cites] Surgery. 1999 Dec;126(6):1200-4 [10598208.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Apr;78(4):867-71 [8157713.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17 ):4744-9 [8062273.001]
  • [Cites] Arch Biochem Biophys. 1996 Jun 1;330(1):24-32 [8651700.001]
  • [Cites] Thyroid. 1998 Sep;8(9):745-9 [9777743.001]
  • [Cites] Thyroid. 2000 Feb;10(2):109-15 [10718546.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4977-83 [14557483.001]
  • (PMID = 16760580.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


28. Fasanella KE, McGrath KM, Sanders M, Brody D, Domsic R, Khalid A: Pancreatic endocrine tumor EUS-guided FNA DNA microsatellite loss and mortality. Gastrointest Endosc; 2009 May;69(6):1074-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor EUS-guided FNA DNA microsatellite loss and mortality.
  • BACKGROUND: The clinical course of pancreatic endocrine tumors (PET) depends on tumor size, the presence of invasion or metastasis, the Ki-67 index, mitoses per high power field, and mutational damage.
  • OBJECTIVE: To evaluate PET EUS-guided FNA (EUS-FNA) microsatellite loss analysis in the context of PET-related mortality.
  • Malignant PET contained multiple microsatellite losses, with a median fractional allelic loss (FAL) of 0.37 (range 0.12-0.69, interquartile range [IQR] 0.23-0.42), significantly different from benign PET, median FAL 0 (range 0-0.18, IQR 0-0.08, P < .0001).
  • [MeSH-major] Biopsy, Fine-Needle. Carcinoma, Islet Cell / genetics. Carcinoma, Islet Cell / ultrasonography. Endosonography. Loss of Heterozygosity / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / ultrasonography. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / genetics. Male. Middle Aged. Neoplasm Staging. Pancreas / pathology. Pancreas / ultrasonography. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2009 May;69(6):1081-4 [19410041.001]
  • (PMID = 19152901.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


29. Nigawara T, Kageyama K, Sakihara S, Takayasu S, Kawahara M, Imai A, Ohyama C, Usui T, Sasano H, Suda T: A male case of nonclassical 21-hydroxylase deficiency first manifested in his sixties with adrenocortical incidentaloma. Endocr J; 2008 May;55(2):291-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nonclassical form of 21-hydroxylase deficiency (NC 21OHD) as a frequent variant on the milder end of the disease spectrum has been widely acknowledged, but its potential contribution to adrenocortical tumorigenesis has not been fully elucidated.
  • The two tumors in the left adrenal, which were interpreted as myelolipoma by imaging studies, were followed by sequential observation, whereas the contralateral large solid tumor associated with inhomogeneous radiological appearance was subsequently removed.
  • The resected tumor was diagnosed an adrenocortical adenoma, which was devoid of P450c21 immunoreactivity.
  • 21OHD is often associated with benign adrenocortical tumors, but bilateral adrenal tumors with heterogeneous components in both adrenals have not been reported to the best of our knowledge.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Hyperplasia, Congenital / diagnosis. Adrenocortical Adenoma / diagnosis. Incidental Findings. Steroid 21-Hydroxylase / genetics

  • Genetic Alliance. consumer health - 21-Hydroxylase Deficiency.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 17ALPHA-HYDROXYPROGESTERONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323673.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 68-96-2 / 17-alpha-Hydroxyprogesterone; 9002-60-2 / Adrenocorticotropic Hormone; EC 1.14.99.10 / Steroid 21-Hydroxylase
  •  go-up   go-down


30. Luo Z, Li J, Qin Y, Ma Y, Liang X, Xian J, Lu D, Wei M, Yang JY, Yang MQ, He Z: Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas. Endocr Pathol; 2006;17(4):387-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the expression of human telomerase catalytic component (hTERT) mRNA, hTERT protein, Ki-67 antigen, and p27kip1 in pheochromocytomas (27 benign, 7 suspected malignant, and 7 malignant), and evaluated the possibility of expressions of these proteins, and hTERT mRNA serve as diagnostic markers for predicting the biological behavior of these tumors.
  • By in situ hybridization, hTERT mRNA was expressed in 5/7 malignant tumors (defined as the presence of metastasis and/or extensive local invasion) as compared with 3/27 benign tumors.
  • All benign tumors exhibited no immunopositivity or <1% of cells stained for Ki-67 antigen.
  • While no statistical difference in p27kip1 expressions was observed among benign, malignant, and suspected malignant tumors, there was a statistical difference between the normal adrenal medulla samples and tumors (p < 0.001).
  • Thus, hTERT mRNA detection by in situ hybridization, hTERT expression, and Ki-67 antigen expression are all useful tools for differentiating malignant from benign pheochromocytomas.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Pheochromocytoma / genetics. RNA, Messenger / metabolism. Telomerase / genetics
  • [MeSH-minor] Adolescent. Adrenal Medulla / metabolism. Adrenal Medulla / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Female. Follow-Up Studies. Humans. In Situ Hybridization. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4280-6 [12970299.001]
  • [Cites] Endocr J. 2004 Feb;51(1):47-52 [15004408.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):246-55 [12640105.001]
  • [Cites] J Pathol. 2000 Jun;191(2):175-80 [10861578.001]
  • [Cites] Nat Med. 1995 Mar;1(3):249-55 [7585042.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4073-81 [11051259.001]
  • [Cites] Am J Gastroenterol. 2002 Apr;97(4):1022-30 [12003383.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5762-8 [15355904.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):401-7 [9033255.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):176-9 [9428495.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1743-52 [15014027.001]
  • [Cites] Nat Med. 1997 Feb;3(2):222-5 [9018243.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1180-4 [2406010.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4346-52 [11035070.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):737-49 [15743786.001]
  • [Cites] BMC Cancer. 2005 Aug 08;5:98 [16086840.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1167-76 [12807729.001]
  • [Cites] Cell. 1998 Mar 6;92(5):587-90 [9506510.001]
  • [Cites] Science. 1997 Aug 15;277(5328):955-9 [9252327.001]
  • [Cites] Nat Med. 1997 Feb;3(2):227-30 [9018244.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1999;107(4):272-5 [10433067.001]
  • [Cites] Toxicol Pathol. 2002 Jul-Aug;30(4):492-500 [12187940.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1168-80 [2172151.001]
  • [Cites] Pathol Oncol Res. 2005;11(1):45-9 [15800682.001]
  • [Cites] Endocr Pathol. 2005 Spring;16(1):23-32 [16000843.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):911-4 [16126869.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):551-66 [11979086.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2626-34 [10893296.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Sep;78(3):201-14 [11595501.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):555-68 [10645224.001]
  • (PMID = 17525487.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


31. Marrache F, Cazals-Hatem D, Kianmanesh R, Palazzo L, Couvelard A, O'Toole D, Maire F, Hammel P, Levy P, Sauvanet A, Ruszniewski P: Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association? Pancreas; 2005 Jul;31(1):79-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association?
  • OBJECTIVES: Pancreatic endocrine tumors (PETs) and intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are rare diseases of the pancreas.
  • Cases of association of endocrine and exocrine neoplasms of the pancreas have been reported, corresponding to mixed or amphicrine tumors.
  • RESULTS: Preoperative diagnosis was unspecified pancreatic tumor (n = 1), IPMN (n = 2), and association of PET and IPMN (n = 3).
  • IPMN involved the main pancreatic duct in 4 patients and was classified as benign (n = 4), borderline (n = 1), or malignant noninvasive (n = 1).
  • CONCLUSION: This study describes a new aspect of endocrine-exocrine pancreatic neoplasm association.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Endocrine Gland Neoplasms / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968252.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 9007-92-5 / Glucagon
  •  go-up   go-down


32. Sato T, Harao M, Nakano S, Jotsuka T, Suda N, Yamashita J: Circulating tumor cells detected by reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA: distinguishing follicular thyroid carcinoma from adenoma. Surgery; 2005 May;137(5):552-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells detected by reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA: distinguishing follicular thyroid carcinoma from adenoma.
  • BACKGROUND: We prospectively tested whether circulating tumor cells could be detected in peripheral blood of patients with thyroid tumors by a reverse transcription-polymerase chain reaction (RT-PCR) to detect carcinoembryonic antigen (CEA) messenger RNA (mRNA).
  • Of 121 preoperative samples from patients with thyroid tumor, 6 were positive (5.0%).
  • Preoperative frequencies of CEA mRNA positivity in benign tumor, papillary carcinoma, follicular variant papillary carcinoma, minimally invasive follicular carcinoma, and widely invasive follicular carcinoma were 0%, 0%, 0%, 44.4% (4/9), and 50.0% (2/4), respectively.
  • CONCLUSIONS: RT-PCR detection of tumor cells in preoperative blood often can distinguish malignant from benign follicular thyroid tumors.
  • [MeSH-major] Adenoma / metabolism. Carcinoembryonic Antigen / metabolism. Carcinoma / metabolism. Goiter, Nodular / metabolism. Neoplastic Cells, Circulating / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adult. Case-Control Studies. Diagnosis, Differential. Follow-Up Studies. Humans. Middle Aged. Prospective Studies. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15855928.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / RNA, Messenger
  •  go-up   go-down


33. Honegger J, Tatagiba M: Craniopharyngioma surgery. Pituitary; 2008;11(4):361-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas grow in the deep-seated hypothalamic area that is paramount for vegetative, emotional and endocrine function, and for maintaining worthwhile life.
  • The benign histological nature of craniopharyngiomas belies their biological behavior and the propensity to recur is a major threat.
  • Surgical treatment has to weigh the risk of hypothalamic damage against the risk of tumor recurrence or progression.
  • [MeSH-major] Craniopharyngioma / surgery. Neurosurgical Procedures. Pituitary Neoplasms / surgery

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1986 Jul;65(1):22-7 [3712025.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):263-9; discussion 269-70 [9007857.001]
  • [Cites] Acta Neurochir (Wien). 1989;99(1-2):11-9 [2667282.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):72-80; discussion 80-1 [12823875.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):817-24 [16049724.001]
  • [Cites] Neurosurgery. 1980 Aug;7(2):111-7 [7422106.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(7):715-8; discussion 719 [9781286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1114-20 [12419438.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):3-11 [2352020.001]
  • [Cites] Cancer. 2007 May 15;109 (10 ):2124-31 [17407137.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):545-50 [1527612.001]
  • [Cites] Eur J Endocrinol. 2006 Mar;154(3):483-9 [16498063.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):251-7 [9950495.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1 Suppl 1):ONS75-83; discussion ONS75-83 [16888556.001]
  • [Cites] Neurosurg Clin N Am. 2006 Apr;17(2):143-8, vi-vii [16793506.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):715-24 [7596502.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):1-10 [8438080.001]
  • [Cites] Surg Neurol. 1992 Mar;37(3):189-96 [1536023.001]
  • [Cites] Neurosurgery. 2004 Sep;55(3):539-47; discussion 547-50 [15335421.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):73-81 [8683285.001]
  • [Cites] Surg Neurol. 1998 Jul;50(1):19-28; discussion 28-9 [9657489.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):1028-35 [10839266.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):189-95 [8407391.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6 Suppl):482-8 [16383245.001]
  • [Cites] J Neurosurg. 2005 Apr;102(4):650-7 [15871507.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2308-14 [17469176.001]
  • [Cites] Br J Neurosurg. 1991;5(6):539-49 [1772600.001]
  • [Cites] Chin Med J (Engl). 2006 Oct 5;119(19):1653-63 [17042979.001]
  • [Cites] Acta Neurochir (Wien). 1986;81(3-4):85-9 [3489356.001]
  • [Cites] J Neurosurg. 1985 Apr;62(4):496-501 [3973718.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] Clin Neurosurg. 1976;23:52-79 [975700.001]
  • [Cites] J Neurosurg. 1969 Apr;30(4):377-90 [4308176.001]
  • [Cites] J Neurosurg. 1980 May;52(5):661-6 [7373393.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):409-17 [6886754.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] J Neurosurg. 2005 May;102(5):832-41 [15926706.001]
  • [Cites] Neurosurgery. 2004 May;54(5):1051-58; discussion 1058-60 [15113458.001]
  • [Cites] Radiother Oncol. 2007 Jan;82(1):90-5 [17161483.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):3-11 [12134929.001]
  • [Cites] Childs Nerv Syst. 1998 Apr-May;14(4-5):179-84 [9660119.001]
  • [Cites] Neurosurgery. 2007 Jan;60(1):46-58; discussion 58-9 [17228252.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2 Suppl):94-102 [16506496.001]
  • [Cites] J Neurosurg. 1997 Jul;87(1):44-51 [9202264.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1053-7; discussion 1057-8 [11846897.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):611-7 [1429082.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:355-66 [16700311.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):400-6 [17367062.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):47-52 [1727168.001]
  • [Cites] Neurosurgery. 2001 Jul;49(1):94-100; discussion 100-1 [11440465.001]
  • [Cites] J Neurosurg. 1985 May;62(5):648-56 [3989587.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):293-8 [12186456.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neurochir (Wien). 1986;83(1-2):1-7 [3799245.001]
  • [Cites] Klin Padiatr. 2003 Nov-Dec;215(6):310-4 [14677094.001]
  • [Cites] J Neurosurg. 1975 Jan;42(1):86-93 [1110394.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):159-66 [11465396.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3):445-51 [15035280.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):291-302; discussion 302-5 [10690718.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):492-9 [12243827.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):437-46 [7673031.001]
  • (PMID = 18636330.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  • [Number-of-references] 65
  •  go-up   go-down


34. Choi YJ, Yun JS, Kim DH: Clinical and ultrasound features of cytology diagnosed follicular neoplasm. Endocr J; 2009;56(3):383-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and ultrasound features of cytology diagnosed follicular neoplasm.
  • The purpose of this study was to identify clinical and ultrasound (US) features of malignancy in patients using cytological results of follicular neoplasm (FN) in the thyroid.
  • Patient histopathology, age, sex, tumor size, and US characteristics and the color flow pattern of the lesions were analyzed and compared between benign and carcinomas.
  • Benign included 78 FA, 8 atypical FA, and 3 Hurthle cell adenomas.
  • The difference of shape, margin, the presence of a halo, internal content, and calcifications was not statistically significant (p value =0.05).
  • [MeSH-major] Adenocarcinoma, Follicular / ultrasonography. Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adult. Aged. Female. Humans. Male. Middle Aged. Thyroid Gland / pathology. Thyroid Gland / ultrasonography. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164864.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Libè R, Fratticci A, Bertherat J: Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer; 2007 Mar;14(1):13-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenocortical cancer (ACC) is a rare tumor with a poor prognosis.
  • By contrast, benign adrenocortical tumors are frequent, underlying the importance of a correct diagnosis of malignancy of such tumors.
  • ACC can be diagnosed by the investigation of endocrine signs of steroid excess, symptoms due to tumor growth or an adrenal incidentaloma.
  • Imaging by CT-scan or MRI shows a large heterogeneous tumor with a low fat content.
  • Careful pathological investigation with the assessment of the Weiss score is important for the diagnosis of malignancy.
  • Tumors localized to the adrenal gland (McFarlane stages 1 and 2) have a better outcome than invasive and metastatic tumors (stages 3 and 4).
  • Tumor removal by a specialized team is crucial for treatment and should always aim at complete removal.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenal Cortex Neoplasms / therapy
  • [MeSH-minor] Genes, Tumor Suppressor. Humans. Oncogenes / genetics


36. Riesco-Eizaguirre G, Santisteban P: New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer; 2007 Dec;14(4):957-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas the prevalence of nodular thyroid disease worldwide is high, malignant conversion from benign thyroid nodules is rare.
  • The most common type of thyroid cancer--papillary thyroid carcinoma--stands out among solid tumours because many of the tumour-initiating events have been identified.
  • All of them function in a single pathway--the RTK/RAS/RAF/MAPK pathway--and obey an 'exclusivity principle': one and only one component of the pathway is mutated in a single tumour.
  • This highlights the requirement of this signal transduction pathway for the transformation to thyroid cancer and paves the way to targeted therapies against a tumour with a mutation in a known gene or any gene upstream of the target.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / therapy. Thyroid Neoplasms / genetics. Thyroid Neoplasms / therapy
  • [MeSH-minor] Humans. Multigene Family. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins c-ret / genetics. Treatment Outcome. Tumor Suppressor Protein p53 / genetics


37. Han XN, Chen B, Ye XD, Wang J, Liu GH: [Clinical manifestation and multiphasic spiral CT scanning features of abdominal pheochromocytoma: report of 70 cases]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among the 70 patients, there were 41 patients with endocrine symptoms related to pheochromocytoma, 15 had a latent pheochromocytoma and the remaining 14 cases presented with a non-functioning pheochromocytoma.
  • Sixty cases had a tumor located in the adrenal gland, while 8 in retroperitoneal space, and 2 cases had both intraadrenal and ectopic lesions simultaneously.
  • Sixty patients had a benign pheochromocytoma, the other 10 had a malignant one or relapse after operation.
  • The average size of the tumor was 5.8 cm (range, 2 approximately 15 cm in the longest diameter).
  • CONCLUSION: Approximately half of the abdominal pheochromocytomas are lack of endocrine symptoms related with their tumors.
  • However, they may display some typical CT characteristics, such as that a small lesion is often homogeneous but hypervascular, a larger tumor may present hemorrhage, necrosis, and cystic change with rich or moderate blood supply.
  • However, when a small tumor has moderate blood supply, it should be differentiated with an adrenal adenoma; when a big one has moderate blood supply, it should be differentiated with other malignant tumors.
  • Furthermore, a part of malignant pheochromocytomas is really difficult to be differentiated from some benign lesions by spiral CT images alone.
  • [MeSH-major] Adrenal Gland Neoplasms / radiography. Pheochromocytoma / radiography. Retroperitoneal Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adenoma / blood supply. Adenoma / radiography. Adenoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiographic Image Enhancement. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538893.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Pezzolla A, Docimo G, Ruggiero R, Monacelli M, Cirocchi R, Parmeggiani D, Conzo G, Gubitosi A, Lattarulo S, Ciampolillo A, Avenia N, Docimo L, Palasciano N: [Incidental thyroid carcinoma: a multicentric experience]. Recenti Prog Med; 2010 May;101(5):194-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From January 2007 to June 2009, 1507 patients for benign disease were subjected to surgery.
  • RESULTS: Histological examination confirmed the diagnosis of benignity in 1339 cases.
  • CONCLUSION: In our study has highlighted the lack of data (medical history, ultrasound, scintigraphic), they may portend the presence of a tumor in the specimen CI.
  • On the basis of these data we feel reasonably acceptable to a close follow-up endocrine surgery, particularly in patients with multinodular disease and stress the need for a multi-specialized team.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / pathology. Thyroid Neoplasms / pathology. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20590015.001).
  • [ISSN] 0034-1193
  • [Journal-full-title] Recenti progressi in medicina
  • [ISO-abbreviation] Recenti Prog Med
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


39. Clerici T, Kolb W, Beutner U, Bareck E, Dotzenrath C, Kull C, Niederle B, German Association of Endocrine Surgeons: Diagnosis and treatment of small follicular thyroid carcinomas. Br J Surg; 2010 Jun;97(6):839-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of small follicular thyroid carcinomas.
  • METHODS: Members of the German Association of Endocrine Surgeons were asked to review patients with mFTC operated on between 1990 and 2005.
  • Most initial diagnoses had to be revised because of incorrect size assessment or incorrect diagnosis (benign adenoma, papillary thyroid carcinoma (PTC), follicular variant of PTC).
  • The diagnosis of mFTC was confirmed in only four patients.
  • As a result of the incorrect histopathological diagnosis, unnecessary completion thyroidectomy and radioiodine ablation were performed in 17 and 20 patients respectively.
  • Histopathological re-evaluation by an experienced pathologist is recommended before embarking on further treatments when a diagnosis of mFTC is made.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Austria. Female. Germany. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Switzerland. Thyroidectomy. Tumor Burden

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473996.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Investigator] Kaserer K; Perren A; Schmid KW; Köberle-Wührer R; Wenzl E; Asari R; Klinge U; Müller G; Kroell KP; Blankenburg C; Voss H; Cupisti K; Witte J; Knoefel WT; Simon D; Lienenlüke RH; Vorländer C; Wacha H; Schabram J; Lorenz K; Dralle H; Wojciechowski B; Kussmann J; Weber Y; Schürmann G; Goretzki PE; Ulitzer H; Eberle A; Mayer M; Stabenow R; Stegmaier C; Bühlmann R; Schlumpf R; Triponez F; Ess SM
  •  go-up   go-down


40. Sundaraiya S, Dizdarevic S, Miles K, Quin J, Williams A, Wheatley T, Zammitt C: Unusual initial manifestation of metastatic follicular carcinoma of the thyroid with thyrotoxicosis diagnosed by technetium Tc 99m pertechnetate scan: case report and review of literature. Endocr Pract; 2009 Jul-Aug;15(5):458-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We present the clinical findings, laboratory results, imaging studies, and surgical pathology report in a man with thyrotoxicosis in whom metastatic well-differentiated thyroid cancer was diagnosed incidentally on a routine TcO4- thyroid scan in the setting of a presumed diagnosis of benign toxic thyroid disease.
  • Scintigraphy revealed sites of metastatic involvement predominantly in the bones along with a cold nodule in the left thyroid lobe, consistent with the primary tumor.
  • CONCLUSION: This case emphasizes the impact of scintigraphic findings on determining the correct management of a patient who would have otherwise undergone inappropriate treatment.
  • Through an extensive literature review, the incidence of malignant involvement in hyperfunctioning thyroid glands and the possible role of sodium iodide symporter expression by thyroid cancer metastatic lesions in preoperative detection of metastatic sites are addressed.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Sodium Pertechnetate Tc 99m. Thyroid Neoplasms / diagnosis. Thyrotoxicosis / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491082.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] A0730CX801 / Sodium Pertechnetate Tc 99m
  • [Number-of-references] 68
  •  go-up   go-down


41. Shibahara T, Onishi T, Franco OE, Arima K, Nishikawa K, Yanagawa M, Hioki T, Watanabe M, Hirokawa Y, Shiraishi T, Sugimura Y: A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population. Anticancer Res; 2006 Sep-Oct;26(5A):3365-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The PSA -158 G/A polymorphism was determined by PCR amplification and restriction digestion assays in 101 organ-confined prostate cancer (PC) patients who underwent radical prostatectomy and 52 controls with benign prostatic hyperplasia.
  • The results revealed that homozygosity for the A allele in Japanese is less common (only 8.5%) than in ethnic populations.
  • There were no significant differences in serum PSA value at the time of diagnosis, differentiation of cancer, pathological stage, cancer volume or ratio of serum PSA/ cancer volume.
  • However, cancer volume after neoadjuvant endocrine therapy was significantly smaller in GG genotype than in AA + AG genotypes.
  • [MeSH-major] Androgens / metabolism. Polymorphism, Genetic. Prostate-Specific Antigen / genetics. Prostatic Neoplasms / genetics. Response Elements / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Electrophoretic Mobility Shift Assay. Genetic Predisposition to Disease. Genotype. Humans. Japan. Male. Neoadjuvant Therapy. Polymerase Chain Reaction. Promoter Regions, Genetic / genetics. Prostatectomy. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / genetics. Prostatic Hyperplasia / therapy. Receptors, Androgen / metabolism. Transfection


42. Pery C, Meurette G, Ansquer C, Frampas E, Regenet N: Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions. Gastroenterol Clin Biol; 2010 Sep;34(8-9):465-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 18-fluorine-18-fluoro-2-deoxyglucose Positron Emission Tomography coupled with computed tomography is a non invasive exploration.
  • Several studies have shown that PET-CT has superior efficacy over conventional imaging techniques in distinguishing a benign pancreatic tumor from a malignant one.
  • It contributes to the diagnosis of cancer in patients with a doubtful mass, much more in case of chronic pancreatitis.
  • PET-CT is also an important help for the diagnosis of cystic tumors of the pancreas; the results can affect the management strategy.
  • It is interesting for the endocrine tumors, particularly since the emergence of new markers.
  • The aim of this paper is to summarize the role and limitations of 18-F-FDG PET-CT in the management of patients with pancreatic lesions (adenocarcinoma, cystic tumors, endocrine tumors, etc…) concerning the malignancy diagnosis, the detection of metastases, the monitoring after non surgical treatments and to evaluate interpretation difficulties, particularly in case of diabetes or chronic pancreatitis.
  • [MeSH-major] Fluorodeoxyglucose F18. Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Cystadenocarcinoma / pathology. Cystadenocarcinoma / radionuclide imaging. Cystadenoma / pathology. Cystadenoma / radionuclide imaging. Humans. Insulinoma / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Neoplasm Staging. Pancreatitis / radionuclide imaging. Prognosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20688444.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Schally AV: [The discovery of hypothalamic hormones and the development of antitumor analogs]. Ann Urol (Paris); 2005 Oct;39 Suppl 3:S46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although after the discovery of GnRH, research was initially directed towards the treatment of infertility, the development during the last twenty-five years of synthetic GnRH analogs has led to major advances in the diagnosis and treatment of endocrine disorders and cancer.
  • Their development is more recent, and they have begun to find a role in prostatic diseases, cancer and benign prostatic hypertrophy.
  • Likewise, this concept of targeted chemotherapy using analogs acting as cytotoxic agent carriers up to the tumor site is the aim of research to evaluate somatostatin and bombesin.
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / physiopathology. Female. Humans. Hypothalamus / physiology. Male. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / physiopathology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302710.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, LHRH; 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 8
  •  go-up   go-down


44. Kusinski M, Wdzieczak-Bakala J, Liu JM, Bignon J, Kuzdak K: AcSDKP: a new potential marker of malignancy of the thyroid gland. Langenbecks Arch Surg; 2006 Feb;391(1):9-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AcSDKP: a new potential marker of malignancy of the thyroid gland.
  • However, no data on the concentration of AcSDKP present in solid tumor tissue are available.
  • The aim of our study was to measure tissue concentration of AcSDKP in benign and malignant lesions of the thyroid gland.
  • The specimens were taken intraoperatively from 20 patients (17 women and 3 men aged 21-68 years): 10 patients with benign nodular goiter and 10 patients with papillary carcinoma of the thyroid gland.
  • RESULTS: The obtained results show that tissue concentration of AcSDKP in malignant thyroid tumors is five times higher when compared to benign lessions.
  • CONCLUSION: We conclude that AcSDKP may play a role in the development of the thyroid gland lesions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. Oligopeptides / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1993 Dec 1;82(11):3307-14 [7694679.001]
  • [Cites] Hypertension. 2004 Feb;43(2):229-36 [14691195.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Feb;86(3):779-82 [2915977.001]
  • [Cites] Eur J Endocrinol. 2002 Feb;146(2):143-51 [11834422.001]
  • [Cites] Int J Cancer. 2004 May 10;109(6):833-8 [15027116.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):239-43 [15254683.001]
  • [Cites] Histopathology. 2005 Sep;47(3):248-56 [16115225.001]
  • [Cites] Thyroid. 2005 Sep;15(9):997-1003 [16187907.001]
  • [Cites] Leukemia. 1993 Jun;7(6):808-12 [8501976.001]
  • [Cites] Wiad Lek. 2001;54(9-10):504-7 [11816293.001]
  • [Cites] Wound Repair Regen. 2006 May-Jun;14(3):306-12 [16808809.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):823-8 [9485041.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Apr;58(4):513-8 [12641636.001]
  • [Cites] J Endocrinol. 1988 Jul;118(1):155-9 [3411280.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):137-48 [15665289.001]
  • [Cites] J Endocrinol. 2000 Sep;166(3):475-80 [11029748.001]
  • [Cites] World J Surg. 2005 Mar;29(3):264-70 [15706436.001]
  • [Cites] Int J Cancer. 1991 Jul 9;48(5):672-7 [2071228.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):353-61; discussion 361-3 [16135921.001]
  • [Cites] FEBS Lett. 1991 Sep 9;289(2):171-5 [1915845.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3014-20 [12480715.001]
  • [Cites] J Natl Cancer Inst. 2003 Nov 19;95(22):1674-80 [14625258.001]
  • [Cites] FEBS Lett. 1990 Nov 12;274(1-2):30-4 [2253778.001]
  • (PMID = 16418871.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oligopeptides; H041538E9P / goralatide
  •  go-up   go-down


45. de Sá SV, Corrêa-Giannella ML, Machado MC, Krogh K, de Almeida MQ, Albergaria Pereira MA, Coelho Siqueira SA, Patzina RA, Ibuki FS, Sogayar MC, Machado MC, Giannella-Neto D: Serpin peptidase inhibitor clade A member 1 as a potential marker for malignancy in insulinomas. Clin Cancer Res; 2007 Sep 15;13(18 Pt 1):5322-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The biological behavior of insulinomas cannot be predicted based on histopathologic criteria in which the diagnosis of malignancy is confirmed by the presence of metastases.
  • EXPERIMENTAL DESIGN: Code Link human bioarrays were used to analyze differences in approximately 20,000 genes between six well-differentiated endocrine tumors of benign behavior compared with one well-differentiated endocrine carcinoma (WDEC) and three metastases of endocrine carcinomas (MEC).
  • Protease serine 2 and complement factor B (from serine-type endopeptidase activity pathway) were respectively confirmed as up-regulated in well-differentiated endocrine tumors of benign behavior (WDET) and in WDEC/MEC.
  • [MeSH-major] Biomarkers, Tumor / genetics. Gene Expression Profiling. Insulinoma / pathology. Plasminogen Activator Inhibitor 1 / genetics. RNA, Messenger / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855650.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Plasminogen Activator Inhibitor 1; 0 / RNA, Messenger; 0 / SERPINE1 protein, human
  •  go-up   go-down


46. Van Effenterre R, Boch AL: [Craniopharyngiomas]. Ann Endocrinol (Paris); 2007 Dec;68(6):412-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are rare benign epithelial tumors, arising from the pituitary stalk or gland and developing in the sellar and suprasellar region, affecting both adults and children.
  • Clinical features essentially include visual disturbances, endocrine deficiencies, and neurological signs.
  • Diagnosis is made on MRI and CT scan, demonstrating a sellar or suprasellar tumor, heterogeneous, with frequent calcifications.
  • This classification allows surgical series comparison, which is of importance since developments and extensions of the tumor can explain surgical difficulties.
  • Because it is an extra-cerebral benign lesion, the ideal goal of treatment should be complete tumor removal with improvement of altered visual functions, minimal deterioration of endocrine function, and no neuropsychological impairment.
  • But the situation of the tumor, its relationship with third ventricle, hypothalamus, optic tract, vascular structures make its removal often difficult.
  • When total removal is impossible, radiotherapy may reduce the risk of a poor evolution.
  • Long term follow up is necessary in these patients, due to medical management of endocrine, visual and psychological problems, and risk of late recurrence.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825241.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 23
  •  go-up   go-down


47. Jiang T, Jiang H, Song XS, Li XC, Li QL: [P53 expression and its clinical significance in prostatic carcinoma]. Zhonghua Nan Ke Xue; 2005 Jun;11(6):448-51, 454
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Formalin-fixed, paraffin-embedded tissue sections from 45 cases of prostatic carcinoma (PCa) and 10 cases of benign prostate hyperplasia (BPH) were analyzed retrospectively with immunohistochemical Elivision staining method.
  • The relationship of P53 expression with prostate cancer stage, grade, PSA, endocrine therapeutic effect and prognosis was evaluated.
  • RESULTS: The positive staining rates of p53 protein expression were 51.1% and 10.0% respectively in patients with PCa and BPH (P < 0.05); 70.0% and 25.0% in PCa patients at pathological stage D and stages A approximately C respectively (P < 0.05); 14.3% and 56.7% in those with Gleason score < or = 7 and > 7 (P < 0.05); 20.0% and 60.0% in those with PSA < or = 10 microg/L and PSA > 10 micro/L (P > 0.05 ); 25.0% and 72.3% in those who responded to endocrine therapy and those who failed to respectively (P < 0.05).
  • CONCLUSION: There were correlations between P53 expression and tumor grade, tumor stage and survival time, so the expression of P53 could be regarded as a prognostic molecular marker and a predictor of endocrine therapeutic effect for prostate cancer.
  • [MeSH-major] Prostatic Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999492.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


48. Kijima Y, Umekita Y, Yoshinaka H, Taguchi S, Owaki T, Funasako Y, Sakamoto A, Yoshida H, Aikou T: Stromal sarcoma with features of giant cell malignant fibrous histiocytoma. Breast Cancer; 2007;14(2):239-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammography and ultrasonography revealed a well-circumscribed and lobulated mass in the upper outer quadrant of the right breast, indicative of a benign breast tumor or mucinous carcinoma.
  • Magnetic resonance imaging revealed a restricted breast tumor without intraductal spread.
  • No metastases were identified in any of the 15 left axillary lymph nodes resected and surgical margins were free from tumor cells.
  • The tumor was negative for both estrogen and progesterone receptor.
  • [MeSH-major] Breast Neoplasms / pathology. Giant Cell Tumors / pathology. Histiocytoma, Malignant Fibrous / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485912.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


49. Elston MS, McDonald KL, Clifton-Bligh RJ, Robinson BG: Familial pituitary tumor syndromes. Nat Rev Endocrinol; 2009 Aug;5(8):453-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial pituitary tumor syndromes.
  • The vast majority of pituitary tumors are benign and occur sporadically; however, they can still result in significant morbidity and even premature mortality through mass effects and hormone dysfunction.
  • Currently, four genes are known to be associated with familial pituitary tumor syndromes: MEN1, CDKN1B, PRKAR1A and AIP.
  • The first three genes are associated with a variety of extrapituitary pathologies, for example, primary hyperparathyroidism with multiple endocrine neoplasia type 1, which might aid identification of these syndromes.
  • Awareness and identification of familial pituitary tumor syndromes is important because of potential associated pathologies and important implications for family members.
  • Here, we review the current knowledge of familial pituitary tumor syndromes.
  • [MeSH-major] Genetic Predisposition to Disease. Pituitary Neoplasms / genetics. Pituitary Neoplasms / pathology
  • [MeSH-minor] Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / genetics. Cyclin-Dependent Kinase Inhibitor p27. Humans. Intracellular Signaling Peptides and Proteins / genetics. Multiple Endocrine Neoplasia / genetics. Multiple Endocrine Neoplasia / pathology. Proto-Oncogene Proteins / genetics. Syndrome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564887.001).
  • [ISSN] 1759-5037
  • [Journal-full-title] Nature reviews. Endocrinology
  • [ISO-abbreviation] Nat Rev Endocrinol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / Intracellular Signaling Peptides and Proteins; 0 / MEN1 protein, human; 0 / PRKAR1A protein, human; 0 / Proto-Oncogene Proteins; 0 / aryl hydrocarbon receptor-interacting protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Number-of-references] 106
  •  go-up   go-down


50. Bednarek-Tupikowska G, Tupikowski K, Akinpelumi BF: [Adrenal myelolipoma]. Pol Merkur Lekarski; 2005 Jan;18(103):107-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a rare, benign, hormonally inactive tumor of the adrenal gland composed of mature fat tissue and hematopoietic tissue in varying amounts.
  • This tumour is discovered during autopsy or USG, CT MRI of the abdomen usually by chance and because of that is included in the group of tumors called incidentaloma.
  • It is usually hormonally inactive but there were several cases in which adrenal myelolipoma coexisted with various endocrine disorders such as Cushing's syndrome, Conn's syndrome, Addison's disease, hirsutism, hermaphroditism, inborn deficiencies of 17- and 21-hydroxylase.
  • Surgical treatment is called for when the diameter of tumor reaches more than 4 cm, tumour shows tendency to fast growth or causes clinical disorders.
  • In cases of small lesions, that show no progression, it is advised to observe the tumor using imaging techniques.
  • [MeSH-major] Adrenal Gland Neoplasms. Myelolipoma
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859562.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 28
  •  go-up   go-down


51. Gessl A, Raber W, Staudenherz A, Becherer A, Koperek O, Hofmann A: Higher frequency of thyroid tumors in the right lobe. Endocr Pathol; 2010 Sep;21(3):186-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the higher cell number in a larger right lobe may confer a higher tumor risk, we investigated the location of benign and malignant lesions to test the hypothesis of a more frequent occurrence in this lobe.
  • In 1,001 consecutive patients with benign thyroid lesions, tumors more frequently occurred in the right lobe (+21.5%, p = 0.0022).
  • Furthermore, in 1,277 thyroid cancer patients with 1,302 thyroid cancers, the right lobe more often harbored the tumor initially (+22.9%, p = 0.0009).
  • Our data show a larger proportion of both benign and malignant tumors in the right thyroid lobe.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 1988 Apr;28(4):409-14 [3056637.001]
  • [Cites] Clin Transl Oncol. 2006 Sep;8(9):681-7 [17005471.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jun;66(6):1240-6 [3259584.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Feb;56(2):260-3 [6822636.001]
  • [Cites] Br J Radiol. 1994 Jun;67(798):519-23 [8032803.001]
  • [Cites] Bull World Health Organ. 1997;75(2):95-7 [9185360.001]
  • [Cites] Acta Radiol. 2002 May;43(3):269-74 [12100323.001]
  • [Cites] Front Neuroendocrinol. 1997 Jul;18(3):354-81 [9237081.001]
  • [Cites] Surg Radiol Anat. 2006 Mar;28(1):25-32 [16374571.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Dec;129(6):505-10 [8109183.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10 ):1027-31 [14606557.001]
  • [Cites] Nuklearmedizin. 1981 Apr;20(2):64-71 [7243602.001]
  • [Cites] Hum Mol Genet. 2007 Feb 1;16(3):276-85 [17164259.001]
  • [Cites] Br J Surg. 1969 May;56(5):351-2 [5781045.001]
  • [Cites] Dtsch Med Wochenschr. 1981 Oct 9;106(41):1338-40 [7274082.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Oct;63(4):918-27 [3488999.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):926-32 [15671771.001]
  • [Cites] Clin Endocrinol (Oxf). 1978 Jun;8(6):483-6 [668154.001]
  • [Cites] Eur J Nucl Med. 1997 Dec;24(12 ):1470-8 [9391181.001]
  • [Cites] Dan Med Bull. 1991 Feb;38(1):87-9 [1878025.001]
  • [Cites] Dtsch Med Wochenschr. 1983 Sep 9;108(36):1355-8 [6884221.001]
  • (PMID = 20532675.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Duerr EM, Mizukami Y, Ng A, Xavier RJ, Kikuchi H, Deshpande V, Warshaw AL, Glickman J, Kulke MH, Chung DC: Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer; 2008 Mar;15(1):243-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to compare a molecular classification with the World Health Organization (WHO) histologic classification, identify genes that may be important for tumor progression, and determine whether gastrointestinal NETs (GI-NETs) differ in their molecular profile from pancreatic NETs (PNETs).
  • Hierarchical clustering of 19 PNETs revealed a 'benign' and 'malignant' cluster that corresponded well with the WHO categories of well-differentiated endocrine tumor (WDET) and well-differentiated endocrine carcinoma (WDEC) respectively.
  • Gene expression profiles reflect the current WHO classification and can distinguish benign from malignant PNETs and also PNETs from GI-NETs.
  • This suggests that molecular profiling may enhance tumor classification schemes.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310291.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK040561; None / None / / P30 DK040561-12; United States / NIDDK NIH HHS / DK / P30 DK040561-12
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


53. Hsieh MS, Liu KL, Tien YW, Shun CT: Combined pancreatic endocrine tumor and serous cystadenoma. J Formos Med Assoc; 2009 Sep;108(9):739-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined pancreatic endocrine tumor and serous cystadenoma.
  • Pancreatic serous cystadenomas account for 1-2% of all exocrine pancreatic tumors, and endocrine tumors account for 1-2% of all pancreatic neoplasms.
  • The combination of pancreatic serous cystadenoma and endocrine tumor is even rarer.
  • Here, we report two cases of combined pancreatic serous adenoma and endocrine tumor.
  • One was a 64-year-old woman with serous cystadenoma and pancreatic endocrine tumor.
  • The other case was a 28-year-old woman with von Hippel-Lindau disease with combined pancreatic serous oligocystic adenoma and well-differentiated malignant endocrine carcinoma.
  • Careful examination of benign serous cystadenoma should be kept in mind during clinical practice, to rule out the possibility of combined malignant endocrine tumor.
  • In addition, von Hippel-Lindau disease should also be suspected when a young adult presents with combination of pancreatic serous cystadenoma and endocrine tumor.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773214.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Singapore
  • [Number-of-references] 15
  •  go-up   go-down


54. Jung EM, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F: Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study. World J Gastroenterol; 2007 Dec 21;13(47):6356-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred patients with histologically confirmed malignant or benign hepatic tumor (maximum size 5 cm) were analyzed.
  • The cut-off of the gray value differences between tumor and normal liver tissue was established using Receiver Operating Characteristic (ROC) analysis 64-line multi-slice computed tomography served as reference method in all cases.
  • RESULTS: One hundred patients with 59 malignant (43 colon, 5 breast, 2 endocrine metastases, 7 hepatocellular carcinomas and 2 kidney cancers) and 41 benign (15 hemangiomas, 7 focal nodular hyperplasias, 5 complicated cysts, 2 abscesses and 12 circumscribed fatty changes) tumors were included.
  • The late venous phase proved to be the most sensitive for classification of the tumor type.
  • Of the 41 benign tumors, 37 were classified as true negative and 4 as false negative, which corresponds to a specificity of 90.2%.
  • [MeSH-major] Contrast Media. Liver Neoplasms / ultrasonography. Phospholipids. Sulfur Hexafluoride. Ultrasonography, Doppler. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081224.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  • [Other-IDs] NLM/ PMC4205454
  •  go-up   go-down


55. Kijima Y, Matsukita S, Yoshinaka H, Owaki T, Aikou T: Adenoma of the nipple: report of a case. Breast Cancer; 2006;13(1):95-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoma of the nipple: report of a case.
  • Examination revealed a firm, well defined and erosive tumor measuring 10 x 11 mm that was sore, crusted, and indurated.
  • There was a slight serosanguineous discharge from the tumor.
  • Cytological material from the tumor obtained from the discharge and by fine needle aspiration (FNA) and scraping showed a papillary cell cluster thought to be a benign papilloma.
  • We performed a tumor resection with preservation of the nipple.
  • The histological diagnosis was adenoma of the nipple.
  • No recurrent tumor has been observed for two years after surgery.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Nipples / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518068.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Asari R, Niederle BE, Scheuba C, Riss P, Koperek O, Kaserer K, Niederle B: Indeterminate thyroid nodules: a challenge for the surgical strategy. Surgery; 2010 Sep;148(3):516-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Because no clinical parameter can establish the final status of a cytologically indeterminate thyroid nodule (ITN) or nodal-metastases in case of malignancy, the initial surgical strategy should define an oncologically adequate procedure with low morbidity.
  • METHODS: The prognostic relevance of sex, age, tumor sizes, multifocality, thyroid function, and recurrence was analyzed in 156 consecutive patients according to the presence of malignancy and nodal metastases.
  • Comparing benign and malignant ITN, no association was found for sex (P = .17), age (P = 1.0), tumor sizes (P = .33, P = .12, P = .19 for < or =30 mm, < or =40 mm, and < or =50 mm, respectively), or thyroid function (P = .26).
  • [MeSH-major] Surgical Procedures, Operative / methods. Thyroid Neoplasms / surgery. Thyroid Nodule / surgery
  • [MeSH-minor] Adult. Female. Humans. Laryngeal Nerves / pathology. Laryngeal Nerves / surgery. Lymph Node Excision. Male. Middle Aged. Neoplasm Metastasis / pathology. Prognosis. Prospective Studies. Recurrence. Retrospective Studies. Thyroid Function Tests. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Surgery.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20338609.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, Wängberg B, Ahlman H: Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl; 2007 Mar;13(3):327-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this consecutive series of 15 patients (5 multivisceral and 10 orthotopic liver transplantations) with well-differentiated carcinoids, or endocrine pancreatic tumors, we allowed higher proliferation rate (Ki67 <10%), large tumor burden, and higher age than previous studies.
  • The survival of grafts and patients compared well with transplantation for benign disease.
  • The recurrence-free survival of both multivisceral and liver transplantation related to the time after transplantation (about 20% at 5 years) despite inclusion of patients with higher risk.
  • The experience with multivisceral transplantation for patients with endocrine tumors of the pancreatic head is still limited.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Liver Transplantation. Neuroendocrine Tumors / secondary. Neuroendocrine Tumors / surgery. Organ Transplantation
  • [MeSH-minor] Adult. Duodenum / transplantation. Female. Humans. Immunosuppression / methods. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Pancreas Transplantation. Pancreatic Neoplasms / pathology. Prognosis. Retrospective Studies. Stomach / transplantation. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 AASLD.
  • (PMID = 17318853.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Tömböl Z, Szabó PM, Molnár V, Wiener Z, Tölgyesi G, Horányi J, Riesz P, Reismann P, Patócs A, Likó I, Gaillard RC, Falus A, Rácz K, Igaz P: Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer; 2009 Sep;16(3):895-906
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MicroRNAs (miRs) are involved in the pathogenesis of several neoplasms; however, there are no data on their expression patterns and possible roles in adrenocortical tumors.
  • Thirty-six tissue samples including normal adrenocortical tissues, benign adenomas, and adrenocortical carcinomas (ACC) were studied by simultaneous miR and mRNA profiling.
  • By calculating the difference between dCT(miR-511) and dCT(miR-503) (delta cycle threshold), ACCs could be distinguished from benign adenomas with high sensitivity and specificity.
  • To our knowledge, this is the first report describing miR expression patterns and pathway analysis in sporadic adrenocortical tumors. miR biomarkers may be helpful for the diagnosis of adrenocortical malignancy.
  • [MeSH-major] Adenoma / genetics. Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Computational Biology / methods. Gene Expression Profiling / methods. MicroRNAs / genetics. Signal Transduction / genetics
  • [MeSH-minor] Adult. Algorithms. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Drug Delivery Systems / methods. Female. Forecasting / methods. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Models, Biological. Organ Specificity / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546168.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


59. Bhargav PR, Mishra A, Agarwal G, Agarwal A, Verma AK, Mishra SK: Phyllodes tumour of the breast: clinicopathological analysis of recurrent vs. non-recurrent cases. Asian J Surg; 2009 Oct;32(4):224-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumour of the breast: clinicopathological analysis of recurrent vs. non-recurrent cases.
  • The mean tumour diameter was 10.5 +/- 5 cm.
  • Preoperative diagnosis with fine needle aspiration cytology could be made in 72% of cases.
  • The histology report was benign, borderline and malignant PT in 28%, 20% and 52% of cases respectively.
  • Except for the extent of primary surgery, there were no significant differences in other clinicopathological factors between the recurrent and non-recurrent groups.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892625.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


60. Zhang YW, Greenblatt DY, Repplinger D, Bargren A, Adler JT, Sippel RS, Chen H: Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid. Ann Surg Oncol; 2008 Oct;15(10):2842-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.
  • BACKGROUND: Hürthle cell neoplasms (HCNs) are rare tumors of the thyroid gland.
  • Medical records of 55 consecutive patients who underwent thyroid resections for the preoperative diagnosis of HCN were reviewed.
  • All HCNs less than 2 cm in diameter were benign.
  • One patient with HCC had recurrence of the disease, but there were no disease-related deaths.
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665423.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / T35 DK062709
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS778770; NLM/ PMC4852735
  •  go-up   go-down


61. Agarwal G, Prasad KK, Kar DK, Krishnani N, Pandey R, Mishra SK: Indian primary hyperparathyroidism patients with parathyroid carcinoma do not differ in clinicoinvestigative characteristics from those with benign parathyroid pathology. World J Surg; 2006 May;30(5):732-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indian primary hyperparathyroidism patients with parathyroid carcinoma do not differ in clinicoinvestigative characteristics from those with benign parathyroid pathology.
  • Palpable parathyroid tumor, advanced skeletal and renal manifestations, and very high serum calcium and parathyroid hormone levels are considered strong predictors.
  • Two patients with PC and 27 (32%) with adenoma had palpable parathyroid tumor.
  • Mean tumor weight (milligram) in carcinoma patients (15,080 +/- 5,638.02) was significantly higher than those with adenoma (5,724 +/- 1,257.9) (P = 0.002).
  • CONCLUSION: Indian patients with parathyroid adenoma, hyperplasia, and carcinoma were not found to differ in their clinical, biochemical, and pathological characteristics except for significantly higher tumor weight in the carcinoma group.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Hyperparathyroidism, Primary / etiology. Parathyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Hyperplasia / diagnosis. India. Male. Middle Aged. Parathyroid Diseases / diagnosis. Predictive Value of Tests

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):344-9 [11859206.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):724-31 [1413841.001]
  • [Cites] World J Surg. 1991 Nov-Dec;15(6):738-44 [1767540.001]
  • [Cites] J Surg Oncol. 2004 Dec 15;88(4):223-8 [15565599.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Sep;89(5):367-75 [7315334.001]
  • [Cites] Surg Clin North Am. 1987 Apr;67(2):343-57 [3551149.001]
  • [Cites] Surgery. 1983 Dec;94(6):906-15 [6648803.001]
  • [Cites] Semin Surg Oncol. 1997 Mar-Apr;13(2):104-13 [9088066.001]
  • [Cites] Ann Surg Oncol. 2005 Jul;12(7):526-32 [15889214.001]
  • [Cites] Arch Surg. 1979 Apr;114(4):468-74 [435060.001]
  • [Cites] Miner Electrolyte Metab. 1987;13(5):305-10 [3312988.001]
  • [Cites] J R Coll Surg Edinb. 1998 Dec;43(6):424-7 [9990797.001]
  • [Cites] World J Surg. 1984 Jun;8(3):392-400 [6464494.001]
  • [Cites] Curr Treat Options Oncol. 2001 Aug;2(4):347-54 [12057115.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Sep;43(3):351-8 [7586606.001]
  • [Cites] Am J Surg. 1985 Apr;149(4):522-7 [3985291.001]
  • [Cites] Rev Invest Clin. 2000 Nov-Dec;52(6):618-24 [11256104.001]
  • [Cites] Eur J Surg. 1996 Oct;162(10):777-81 [8934106.001]
  • [Cites] Endocr Rev. 1982 Spring;3(2):218-26 [7044770.001]
  • [Cites] Surgery. 1990 Jan;107(1):13-9 [2296753.001]
  • [Cites] Endocr Pathol. 2005 Spring;16(1):49-52 [16000846.001]
  • [Cites] J Pak Med Assoc. 1999 Aug;49(8):194-8 [10641503.001]
  • [Cites] Cancer. 1973 Mar;31(3):600-5 [4693587.001]
  • [Cites] Br J Surg. 2001 May;88(5):708-14 [11350446.001]
  • [Cites] Surgery. 1991 Oct;110(4):704-8 [1925959.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Jul;49(3):448-50 [17001919.001]
  • [Cites] Hum Pathol. 1986 May;17(5):520-7 [3699813.001]
  • [Cites] Pathol Annu. 1981;16(Pt 2):1-24 [7036057.001]
  • [Cites] Indian J Med Res. 1985 Jun;81:607-12 [4054967.001]
  • [Cites] Endocr Pract. 2002 Jul-Aug;8(4):266-70 [12173912.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):169-73 [9435436.001]
  • [Cites] Ann Acad Med Singapore. 2001 Jan;30(1):66-70 [11242630.001]
  • [Cites] Ann Saudi Med. 2005 Jan-Feb;25(1):29-35 [15822491.001]
  • [Cites] Arch Surg. 1979 Apr;114(4):475-80 [435061.001]
  • [Cites] Surgery. 2002 Dec;132(6):1075-83; discussion 1083-5 [12490858.001]
  • [Cites] Adv Anat Pathol. 2005 Mar;12(2):53-61 [15731573.001]
  • [Cites] World J Surg. 1988 Aug;12 (4):517-21 [3420934.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jan;47(1):39-40 [15471124.001]
  • [Cites] Rev Med Chil. 1993 Mar;121(3):265-72 [8248638.001]
  • (PMID = 16680588.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Perrier ND, Kennamer DL, Bao R, Jimenez C, Grubbs EG, Lee JE, Evans DB: Posterior retroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolated metastases. Ann Surg; 2008 Oct;248(4):666-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior retroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolated metastases.
  • OBJECTIVE: Posterior retroperitoneoscopic adrenalectomy (PRA) is a minimally invasive approach to removal of the adrenal gland.
  • METHODS: The prospective endocrine surgery database at a tertiary care center was used to capture all patients who underwent PRA between October 2005 and February 2008.
  • Mean tumor size was 3.4 cm.
  • PRA may be the preferred technique for removing benign adrenal tumors and isolated metastases.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy / methods. Retroperitoneal Space / surgery
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Treatment Outcome


63. Garnett MR, Puget S, Grill J, Sainte-Rose C: Craniopharyngioma. Orphanet J Rare Dis; 2007;2:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are benign slow growing tumours that are located within the sellar and para sellar region of the central nervous system.
  • The point prevalence of this tumour is approximately 2/100,000.
  • The onset of symptoms is normally insidious with most patients at diagnosis having neurological (headaches, visual disturbances) and endocrine (growth retardation, delayed puberty) dysfunctions.
  • The neuroradiological diagnosis is mainly based on the three components of the tumour (cystic, solid and calcified) in the characteristic sellar/para sellar location.
  • Definitive diagnosis is made following histological examination of a surgical specimen.
  • The differential diagnosis includes other tumours in this region (pituitary adenoma), infectious or inflammatory processes (eosinophilic granuloma), vascular malformations (aneurysm) and congenital anomalies (Rathke's cleft cyst).
  • The current treatment is gross total excision of the tumour, if there is no hypothalamic invasion or, in the presence of hypothalamic invasion, a sub-total resection with post-operative radiotherapy.
  • Endocrine disturbances are normally permanent and need careful replacement.
  • [MeSH-major] Craniopharyngioma / diagnosis. Craniopharyngioma / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / therapy
  • [MeSH-minor] Adult. Child. Diagnosis, Differential. Humans. Medical Oncology / methods. Prognosis. Quality of Life

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):764-9 [10603020.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):255-63 [10760417.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1053-7; discussion 1057-8 [11846897.001]
  • [Cites] Acta Neurochir (Wien). 2002 Apr;144(4):403-4 [12021891.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):533-42 [12062594.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):1-2; discussion 2 [12134898.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):3-11 [12134929.001]
  • [Cites] Dev Med Child Neurol. 2004 Apr;46(4):220-9 [15077699.001]
  • [Cites] J Neurosurg. 1970 Dec;33(6):689-707 [5488801.001]
  • [Cites] Neurosurgery. 1982 Jul;11(1 Pt 1):12-5 [6287341.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):409-17 [6886754.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Oct;47(10):1075-80 [6502164.001]
  • [Cites] Neurochirurgie. 1984;30(5):347-9 [6521815.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:350-8 [3628817.001]
  • [Cites] Childs Nerv Syst. 1988 Apr;4(2):97-9 [3401877.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):3-11 [2352020.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):534-40 [2398383.001]
  • [Cites] Neurology. 1991 May;41(5):726-9 [2027490.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):1025-6 [2033440.001]
  • [Cites] Neurol Clin. 1991 May;9(2):453-65 [1944109.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):47-52 [1727168.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:11-7 [7841069.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jul;81(7):2734-7 [8675604.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):73-81 [8683285.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] Pediatr Hematol Oncol. 2005 Mar;22(2):89-101 [15804994.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E6 [16048292.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):729-46 [16044343.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):808-16 [16075214.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):691-5 [16078079.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):719-24 [16133276.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:289-93 [16700303.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:299-319 [16700305.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:325-7 [16700307.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:329-35 [16700308.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:337-40 [16700309.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:389-94 [16700315.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:407-12 [16700318.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • (PMID = 17425791.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 43
  • [Other-IDs] NLM/ PMC1855047
  •  go-up   go-down


64. Fugazzola L: Expanding use of recombinant hTSH. Ann Endocrinol (Paris); 2007 Sep;68(4):220-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical benefits of recombinant human thyroid-stimulating hormone (rhTSH; Thyrogen, Genzyme Corp., Cambridge, MA, USA) are well established as an alternative stimulation procedure to thyroid hormone withdrawal in the follow-up of thyroid cancer patients. rhTSH has the advantage to avoid both hypothyroidism, with a major impact on the quality of life, and the side effects on tumor growth related to the long-lasting TSH increase.
  • More recently, alternative uses have been proposed, including treatment of nodular goiter, TSH stimulation to enhance PET scanning and chemotherapy treatment, and differential diagnosis of congenital hypothyroidism.
  • In benign thyroid diseases, rhTSH administration increases thyroid uptake resulting in a more homogeneous distribution of the tracer, and allows to reduce the dose of 131I maintaining the same effects on thyroid shrinkage.
  • Finally, rhTSH testing has been proved to be safe and to lead, in association with ultrasound, to the differential diagnosis of congenital hypothyroidism during L-thyroxine, allowing the appropriate clinical/genetic management of the disease and thus representing a valuable alternative to L-thyroxine withdrawal.
  • [MeSH-minor] Congenital Hypothyroidism / diagnosis. Diagnosis, Differential. Goiter, Nodular / radiotherapy. Humans. Iodine Radioisotopes / therapeutic use. Positron-Emission Tomography. Recombinant Proteins / therapeutic use. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689475.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Recombinant Proteins; 9002-71-5 / Thyrotropin
  • [Number-of-references] 20
  •  go-up   go-down


65. Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA: Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery; 2008 Jun;143(6):759-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic differentiation between benign and malignant tumors is difficult, the latter diagnosed by the presence of metastatic disease or recurrence.
  • AIM: To determine if postoperative histologic evaluation using the previously proposed Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and cell cycle/apoptosis markers can predict patients at risk for recurrence.
  • A senior endocrine pathologist, blinded to clinical outcome, reviewed the histopathologic characteristics of all cases using the PASS system.
  • This pheochromocytoma scoring system is based on the presence of 12 different histologic parameters, including tumor necrosis, mitotic rate, tumor cell spindling, and the presence of large cell nests.
  • In addition, we constructed a tissue microarray of all 5 malignant tumors and 41 of the benign tumors.
  • By immunostaining of the tissue microarray, we assessed the expression of 7 different cell cycle/apoptosis-related genes (p53, Ki-67, Bcl-2, mdm-2, cyclin D1, p21, and p27).
  • RESULTS: Forty-three patients had a benign clinical course while 5 patients harbored a clinically malignant pheochromocytoma.
  • Tumor necrosis (focal or confluent) was a particularly powerful indicator of malignancy present in 4 of 5 patients (80%) with malignant tumors, but only in 3 of 42 cases (7%) with benign neoplasms (P = .0009).
  • The presence of a high mitotic rate (>3/10 high power fields) and tumor cell spindling significantly correlated with malignancy (P = .026 and .041, respectively).
  • There was a highly significant difference in PASS scores between benign and malignant cases (P = .0003).
  • Ki-67-positive tumor had a significantly higher chance of harboring tumor necrosis than Ki-67-negative neoplasms (P < .01).
  • There was no difference in staining between benign and malignant pheochromocytomas using p53, Bcl-2, mdm-2, cyclin D1, p21, and p27. CONCLUSIONS:.
  • (1) A PASS score of <4 predicted benign pheochromocytomas. (2) All malignant pheochromocytomas had a PASS score >/=6, which was significantly higher compared with the benign lesions.
  • Ki-67 may help identify those neoplasms at risk for recurrence by prompting the pathologist to look aggressively for adverse histologic features.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / pathology. Apoptosis. Cell Cycle. Gene Expression Regulation, Neoplastic. Neoplasm Recurrence, Local / genetics. Pheochromocytoma / diagnosis. Pheochromocytoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Ki-67 Antigen / genetics. Ki-67 Antigen / metabolism. Male. Middle Aged. Necrosis / diagnosis. Necrosis / genetics. Necrosis / pathology. Predictive Value of Tests. Prognosis. Prospective Studies. Risk Factors. Severity of Illness Index. Single-Blind Method


66. Geller JL, Azer PC, Weiss LM, Mertens RB: Pigmented adrenocortical carcinoma: case report and review. Endocr Pathol; 2006;17(3):297-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Darkly pigmented adrenocortical neoplasms are rare tumors that are often referred to as "black adenomas," indicative of both their pigmented nature and their invariably benign clinical behavior in previously reported cases.
  • We herein describe an exceptional case of a malignant pigmented adrenocortical neoplasm, with late recurrence and metastasis.
  • At age 53, this female patient was diagnosed with Cushing's syndrome and underwent a laparoscopic right adrenalectomy, revealing a 3 cm well-circumscribed, darkly pigmented adrenocortical tumor.
  • The tumor exhibited several atypical histologic features and was diagnosed as an atypical pigmented adrenal cortical neoplasm of uncertain malignant potential.
  • At subsequent exploratory laparotomy, three separate tumor nodules exhibiting varying degrees of pigmentation and ranging from 2.2 to 3.3 cm maximum dimension were excised.
  • Histologically, the tumor nodules were consistent with local recurrence/metastasis of the patient's previously excised pigmented adrenocortical neoplasm.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / secondary. Pigmentation. Retroperitoneal Neoplasms / secondary
  • [MeSH-minor] Adrenalectomy. Cushing Syndrome / etiology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] Am J Clin Pathol. 1987 Mar;87(3):334-41 [2435143.001]
  • [Cites] Hum Pathol. 1972 Sep;3(3):317-25 [5046900.001]
  • [Cites] Am J Clin Pathol. 1974 Jul;62(1):97-103 [4134750.001]
  • [Cites] Arch Pathol Lab Med. 1985 Feb;109(2):198-200 [3838445.001]
  • [Cites] CA Cancer J Clin. 1987 Nov-Dec;37(6):348-65 [3119168.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):265-80 [15163302.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1901-4 [15274373.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] J Natl Med Assoc. 2001 Jan;93(1):37-9 [12653379.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):603-14 [9591731.001]
  • [Cites] Mod Pathol. 1992 Jan;5(1):23-9 [1542635.001]
  • [Cites] Cancer. 1981 May 1;47(9):2153-61 [7226109.001]
  • [Cites] Arch Pathol Lab Med. 1991 Aug;115(8):813-5 [1863192.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):e125-8 [15387689.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):765-9 [2743269.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 17308367.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Treska V, Wirthová M, Hadravská S, Mukensnábl P, Kuntscher V, Kreuzberg B, Lisá L, Kozák K: [Giant bilateral adrenal myelolipoma associated with congenital adrenal hyperplasia]. Zentralbl Chir; 2006 Feb;131(1):80-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ein bilaterales Riesenmyelolipom der Nebennieren in Kombination mit kongenitaler adrenaler Hyperplasie.
  • BACKGROUND: Myelolipoma is a rare benign tumor formed by mature fat tissue with strata of haematopoiesis.
  • It is usually localized in the region of the adrenal gland.
  • Myelolipomas are mostly clinically inert, only a small number of them are associated with Cushing's type of endocrine disorders, Conn's syndrome, Addison's disease, etc.
  • PATIENT AND METHODS: The authors present a rare case of a giant bilateral myelolipoma emerging out of the adrenal gland cortex in a congenital adrenal hyperplasia, with steroid 21-hydroxylase deficiency, in a woman with pronounced virilism.
  • CONCLUSIONS: The coincidence of myelolipoma and congenital disorder with subsequent overproduction of the adrenocorticotropin hormone and androgens, might be explained by the incipient of myelolipoma through chronic hormonal stimulation of the adrenal gland cortex.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / surgery. Adrenal Hyperplasia, Congenital / complications. Adrenal Hyperplasia, Congenital / surgery. Myelolipoma / complications. Myelolipoma / surgery. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adrenal Glands / pathology. Adrenalectomy. Female. Humans. Middle Aged. Steroid 21-Hydroxylase / blood. Tomography, X-Ray Computed


68. Juhlin C, Larsson C, Yakoleva T, Leibiger I, Leibiger B, Alimov A, Weber G, Höög A, Villablanca A: Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer; 2006 Jun;13(2):509-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inactivation of the hyperparathyroidism-jaw tumour syndrome (HPT- JT) gene, HRPT2, was recently established as a genetic mechanism in the development of parathyroid tumours.
  • Its encoded protein parafibromin has tumour-suppressor properties that play an important role in tumour development in the parathyroids, jaws and kidneys.
  • Both high and low cyclin D1 levels were found among HRPT2-mutated and -unmutated tumours, suggesting that these events are not mutually exclusive in parathyroid tumour development.
  • The presented data suggest that in the majority of benign parathyroid tumours the expression of parafibromin remains unaltered, while the loss of parafibromin expression is strongly indicative of gene inactivation through mutation of the HRPT2 gene.
  • [MeSH-major] Adenoma / genetics. Parathyroid Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728578.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


69. Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO: Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol; 2010 Jun;21(2):80-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Difficulties in diagnosis of thyroid lesions, even with histologic analysis, are well known.
  • This study has been carried on to evaluate the role of immunohistochemical markers including galectin-3, Hector Battifora mesothelial cell-1 (HBME-1), and cytokeratin-19 in the diagnosis and differential diagnosis of benign and malignant thyroid lesions.
  • The expressions of galectin-3, HBME-1, and cytokeratin-19 were tested in formalin-fixed, paraffin-embedded tissues from 458 surgically resected thyroid lesions including non-neoplastic and neoplastic lesions.
  • The use of galectin-3, HBME-1, and cytokeratin-19 may provide significant contributions in the differential diagnosis of malignant thyroid tumors.
  • Although focal galectin-3, HBME-1, and cytokeratin-19 expression may be encountered in benign lesions, diffuse positive reactions for these three markers are characteristic of malignant lesions.
  • It has concluded that cytokeratin-19 alone and its combinations with other markers were more sensitive in accurate diagnosis of papillary carcinoma than the other combinations; meanwhile, there were similar results for follicular carcinomas with HBME-1 alone and its combinations.
  • [MeSH-major] Biomarkers, Tumor / analysis. Galectin 3 / biosynthesis. Keratin-19 / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Sensitivity and Specificity. Thyroid Diseases / diagnosis. Thyroid Diseases / genetics. Thyroid Diseases / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2002 Fall;13(3):207-11 [12446919.001]
  • [Cites] Endocr J. 2003 Apr;50(2):173-7 [12803237.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Diagn Pathol. 2008 Feb 06;3:5 [18254952.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Endocr Pathol. 2006 Fall;17(3):225-34 [17308359.001]
  • [Cites] Am J Clin Pathol. 1989 Nov;92(5):654-8 [2479256.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1631-7 [16998461.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Singapore Med J. 2008 Apr;49(4):333-8 [18418527.001]
  • [Cites] Histopathology. 2002 Sep;41(3):236-43 [12207785.001]
  • [Cites] Pathology. 2005 Aug;37(4):296-8 [16194828.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):428-33 [10821488.001]
  • [Cites] Histopathology. 2005 Aug;47(2):209-14 [16045783.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2811-26 [18612701.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):541-6 [15529186.001]
  • [Cites] J Korean Med Sci. 2005 Oct;20(5):853-9 [16224162.001]
  • [Cites] Virchows Arch. 1997 Mar;430(3):239-45 [9099982.001]
  • [Cites] Histopathology. 2004 Jul;45(1):39-46 [15228442.001]
  • [Cites] Endocr Pathol. 2008 Summer;19(2):92-6 [18581271.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] Histopathology. 2006 Jun;48(7):795-800 [16722927.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):309-12 [14999471.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4792-6 [12364475.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):87-95 [15742329.001]
  • [Cites] Head Neck. 2004 Nov;26(11):960-6 [15386597.001]
  • [Cites] J Korean Med Sci. 2007 Aug;22(4):621-8 [17728499.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2475-84 [10357421.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3015-20 [9679965.001]
  • [Cites] Ann Intern Med. 2005 Jun 7;142(11):926-31 [15941700.001]
  • (PMID = 20198455.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19
  •  go-up   go-down


70. Miyamoto H, Molena DA, Schoeniger LO, Haodong Xu: Solitary fibrous tumor of the pancreas: a case report. Int J Surg Pathol; 2007 Jul;15(3):311-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pancreas: a case report.
  • Solitary fibrous tumor (SFT) is an unusual mesenchymal neoplasm that most often arises in the pleura; however, it has recently been described in a number of extrapleural sites.
  • This report describes an extremely rare case of a benign SFT arising in the pancreas.
  • An endocrine tumor was clinically suspected.
  • Microscopically, the tumor was composed of bland uniform spindle cells arranged between collagen bundles.
  • Based on the light microscopic morphology and immunohistochemical staining profile, the diagnosis of SFT was rendered.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652547.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


76. Chang MC, Xiao S, Nosé V: Clinicopathologic and immunohistochemical correlation in sporadic pancreatic endocrine tumors: possible roles of utrophin and cyclin D1 in malignant progression. Hum Pathol; 2007 May;38(5):732-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and immunohistochemical correlation in sporadic pancreatic endocrine tumors: possible roles of utrophin and cyclin D1 in malignant progression.
  • Pancreatic endocrine tumors (PETs), both functioning and nonfunctioning, are usually well differentiated and progress slowly.
  • A tumor associated with poorer prognostic features may be considered "uncertain" in behavior, but the malignant classifications are reserved for tumors showing clear signs of aggressive behavior.
  • Sporadic PETs resected or biopsied from 40 patients were identified and classified using WHO criteria (19 benign/uncertain, 21 malignant).
  • Utrophin localized to cell membranes (76% in malignant versus 21% in benign/uncertain PETs, P < .0006) and cyclin D1 staining showed nuclear positivity (67% in malignant versus 17% in benign/uncertain PETs, P < .003).
  • [MeSH-major] Cyclin D1 / physiology. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Utrophin / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306326.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Utrophin; 136601-57-5 / Cyclin D1
  •  go-up   go-down


77. Avcu S, Ozen O, Bulut MD, Bora A: Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings. N Am J Med Sci; 2009 Nov;1(6):305-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings.
  • CONTEXT: Carcinoid tumors represent a group of well-differentiated tumors originating from the diffuse endocrine system outside the pancreas and thyroid.
  • Various sites of origin of this neoplasm are appendix - 30-45%, small bowel - 25-35% (duodenum 2%, jejunum 7%, ileum 91%, multiple sites 15-35%), rectum 10-15%, caecum - 5%, and stomach - 0.5%.
  • CASE REPORT: Here we report a case of primary jejunal carcinoid tumor in a 66-year-old woman metastasizing to liver with ultrasonography, computed tomography, and diffusion-weighted magnetic resonance imaging (DWI) findings.
  • CONCLUSION: Primary jejunal carcinoid tumor is a rare entity.
  • DWI can help in the differential diagnosis of hepatic hypervascular metastatic mass lesions from benign ones, as well as in the diagnosis of carcinoid tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22666712.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3364631
  • [Keywords] NOTNLM ; Carcinoid / diffusion weighted MRI / jejunum / metastases / small bowel
  •  go-up   go-down


78. Rivkine E, Goasguen N, Chelbi E, Couvelard A, Vullierme MP, Vilgrain V, Hammel P, Sauvanet A: [Cystic teratoma of the pancreas]. Gastroenterol Clin Biol; 2007 Nov;31(11):1016-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The preoperative diagnosis of cystic tumours of the pancreas can be difficult.
  • It is usually based on morphological and biological (i.e., cyst fluid content of tumour markers) data.
  • We report here the case of a 45-year old woman who was operated on for a benign cystic mature teratoma with endocrine component and high concentrations in cyst fluid CEA and CA 72.4 which was evocative of a malignant mucinous cystadenoma.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Antigens, Tumor-Associated, Carbohydrate / metabolism. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Cystadenoma, Mucinous / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166898.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-72-4 antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


79. Brown B, Ram A, Clayton P, Humphrey G: Conservative management of bilateral Sertoli cell tumors of the testicle in association with the Carney complex: a case report. J Pediatr Surg; 2007 Sep;42(9):E13-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large cell calcifying Sertoli cell tumor of the testicle is a rare, hormonally active sex cord-stromal tumor seen in patients with Carney complex.
  • The availability of specific antiestrogen drugs means that bilateral orchiectomy for this benign tumor may no longer be warranted.
  • In: Rowe MI, O'Neill JA, Grosfeld JL et al, editors.
  • [MeSH-major] Multiple Endocrine Neoplasia / diagnosis. Sertoli Cell Tumor / therapy. Testicular Neoplasms / therapy

  • Genetic Alliance. consumer health - Carney Complex.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848226.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Lai EW, Perera SM, Havekes B, Timmers HJ, Brouwers FM, McElroy B, Adams KT, Ohta S, Wesley RA, Eisenhofer G, Pacak K: Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. Endocrine; 2008 Aug-Dec;34(1-3):96-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma.
  • Signs and symptoms associated with pheochromocytomas are predominantly caused by catecholamine excess, but tend to be highly variable and non-specific.
  • In this study, we evaluated 23 male and 35 female pheochromocytoma patients for symptoms and signs of pheochromocytoma with special regard to gender-related differences in presentation.
  • Subgroup analyses and multiple regression analysis revealed gender differences to be irrespective of benign or malignant disease, use of adrenoceptor-blockade, age and biochemical phenotype.
  • We conclude female patients have significantly more self-reported pheochromocytoma signs and symptoms than male patients irrespective of biochemical phenotype and tumor presentation which may be related to distinct catecholamine receptor sensitivity.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Pheochromocytoma / diagnosis. Sex Characteristics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hum Hypertens. 2007 Mar;21(3):239-45 [17167522.001]
  • [Cites] Clin Chem. 1993 Jan;39(1):97-103 [8419068.001]
  • [Cites] Cell Mol Life Sci. 2003 Sep;60(9):1982-9 [14523558.001]
  • [Cites] Qual Life Res. 2005 Oct;14(8):1825-33 [16155770.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):779-86 [17200167.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):759-63; discussion 763-4 [1413846.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2008 Jan;5(1):22-9 [18094670.001]
  • [Cites] Int J Obes Relat Metab Disord. 1993 Dec;17 Suppl 3:S43-6; discussion S68 [8124400.001]
  • [Cites] Lung Cancer. 2008 Apr;60(1):113-24 [17976859.001]
  • [Cites] J Clin Pharmacol. 1998 Jul;38(7):618-24 [9702846.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):87-94 [15762191.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):365-73 [11162946.001]
  • [Cites] Stress. 2007 Jun;10(2):195-203 [17514588.001]
  • [Cites] J Am Coll Cardiol. 2000 Oct;36(4):1233-8 [11028476.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Nov;92(11):4069-79 [17989126.001]
  • [Cites] Clin Chem. 2005 Apr;51(4):735-44 [15718487.001]
  • [Cites] Pharmacol Rev. 2004 Sep;56(3):331-49 [15317907.001]
  • [Cites] Neuropsychopharmacology. 1997 Apr;16(4):298-310 [9094148.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):539-53 [12920154.001]
  • [Cites] Hypertension. 2008 Apr;51(4):1203-9 [18259012.001]
  • [Cites] Clin Pharmacol Ther. 2005 May;77(5):388-403 [15900285.001]
  • [Cites] Circ Res. 1987 Jul;61(1):86-98 [3038368.001]
  • [Cites] Clin Pharmacol Ther. 1996 Jul;60(1):99-104 [8689818.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):139-43 [15263057.001]
  • (PMID = 18982461.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


81. Carney JA: Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors. J Clin Endocrinol Metab; 2009 Oct;94(10):3656-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors.
  • BACKGROUND: Two young women, each with paraganglioma and gastric stromal tumor, were encountered in the middle 1970s.
  • Five additional patients with gastric stromal tumor, paraganglioma, and pulmonary chondroma were found, and all were young women.
  • The gastric lesion was usually the presenting tumor (75%), followed by the lung lesion (15%) and the paraganglionic tumor (10%).
  • The pulmonary tumors were asymptomatic and benign.
  • FOLLOW-UP: At follow-up, 80% of the patients were alive, two thirds with pulmonary chondroma, 25% with metastatic or residual gastric stromal tumor, and 5% with primary or metastatic paraganglioma.
  • Twenty percent of the patients were dead, usually from metastatic gastric stromal tumor, less frequently from metastatic paraganglioma.
  • CONCLUSION: The Carney triad is a chronic, persistent, indolent but sometimes fatal disorder of unknown etiology.
  • [MeSH-major] Adenoma. Adrenal Cortex Neoplasms. Chondroma. Esophageal Neoplasms. Leiomyoma. Lung Neoplasms. Multiple Endocrine Neoplasia. Neoplastic Syndromes, Hereditary / pathology. Paraganglioma
  • [MeSH-minor] Adolescent. Carotid Body Tumor / pathology. Chronic Disease. Female. Follow-Up Studies. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Pheochromocytoma / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for carney triad .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723753.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


82. Cupisti K, Raffel A, Ramp U, Wolf A, Donner A, Krausch M, Eisenberger CF, Knoefel WT: Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter. Endocr J; 2005 Apr;52(2):281-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter.
  • We report the case of a 52-year-old man with the history of two previous thyroid operations for benign goiters, who developed a recurrent goiter.
  • There is no known common cause of these three different tumor types and they developed most independently from each other.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Medullary / pathology. Carcinoma, Papillary / pathology. Goiter / complications. Neoplasms, Multiple Primary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Recurrence. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863962.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Kajor M, Ziaja J, Lange D, Król R, Ciupińska-Kajor M, Turska-d'Amico M, Maka B, Cierpka L: [Analysis of morphology of adrenal pheochromocytoma as regards their potential malignancy]. Endokrynol Pol; 2005 Nov-Dec;56(6):911-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the study is to analyse the morphology of pheochromocytomas on the basis of Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) in order to estimate their potential malignancy.
  • The diagnosis of pheochromocytoma was establish before surgery in 87.5%.
  • 12.5% of patients were referred to surgery on the basis of tumour diameter (range 70 to 102 mm).
  • RESULTS: In pathological examination benign pheochromo-cytoma was diagnosed in 39 presented patients.
  • CONCLUSION: Analysis of pheochromocytoma in PASS is only of rough character and does not allow for clear-cut histological diagnosis of benign and malignant tumours.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Pheochromocytoma / pathology. Pheochromocytoma / secondary
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multiple Endocrine Neoplasia Type 2a / pathology. Neoplasm Staging. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821210.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


84. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fèvre-Montange M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J, Trouillas J: A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer; 2007 Sep;14(3):887-900
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although most pituitary tumors are benign, some are invasive or aggressive.
  • Using radiology and histological methods, we classified 25 human PRL tumors into three groups (non-invasive, invasive, and aggressive-invasive) and compared them with a model of transplantable rat PRL tumors with benign and malignant lineages.
  • Combining histological(mitoses and labeling for Ki-67, P53, pituitary transforming tumor gene (PTTG), and polysialic acid neural cell adhesion molecule) and transcriptomic (microarrays and q-RTPCR) methods with clinical data (post-surgical outcome with case-control statistical analysis), we found nine genes implicated in invasion (ADAMTS6, CRMP1, and DCAMKL3) proliferation (PTTG, ASK, CCNB1, AURKB, and CENPE), or pituitary differentiation (PITX1) showing differential expression in the three groups of tumors (P = 0.015 to 0.0001).
  • These combined histological and transcriptomic analyses improve the pathological diagnosis of PRL tumors, indicating a reliable procedure for predicting tumor aggressiveness and recurrence potential.
  • The similar gene profiles found between non-invasive human and benign rat tumors, as well as between aggressive-invasive human and malignant rat tumors provide new insights into malignancy in human pituitary tumors.
  • [MeSH-major] Biomarkers, Tumor / isolation & purification. Cell Proliferation. Molecular Diagnostic Techniques. Pituitary Neoplasms / genetics. Pituitary Neoplasms / pathology. Prolactinoma / genetics. Prolactinoma / pathology
  • [MeSH-minor] Animals. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Prognosis. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914117.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Dhellemmes P, Vinchon M: Radical resection for craniopharyngiomas in children: surgical technique and clinical results. J Pediatr Endocrinol Metab; 2006 Apr;19 Suppl 1:329-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are benign suprasellar tumors; however, their tendency to recur after resection and the risks associated with aggressive tumor resection pose a surgical dilemma.
  • No patient died in the operative period; three patients died 6 months to 8 years after surgery of endocrine-related cause or sudden death.
  • Tumor progression occurred in 93% of cases after subtotal resection versus 43% after total resection.
  • Visual deficits were often stabilized or improved after surgery, but worsened in 30% because of surgical damage or tumor recurrence.
  • Hypothalamic damage was generally associated with intraventricular extension of the tumor recurrence and re-operations, especially through combined approaches.
  • [MeSH-major] Craniopharyngioma / surgery. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Hormone Replacement Therapy. Humans. Male. Neoplasm Recurrence, Local / therapy. Neuropsychological Tests. Postoperative Care. Radiosurgery. Retrospective Studies. Rhenium / therapeutic use. Tomography, X-Ray Computed. Treatment Outcome. Visual Acuity

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700308.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7440-15-5 / Rhenium
  •  go-up   go-down


86. Mittendorf EA, Liu YC, McHenry CR: Giant insulinoma: case report and review of the literature. J Clin Endocrinol Metab; 2005 Jan;90(1):575-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An insulinoma is a rare pancreatic endocrine tumor that is typically sporadic, solitary, and less than 2 cm in diameter.
  • Ninety percent or more of all insulinomas are benign.
  • We report a case of a giant pedunculated insulinoma, measuring 9 cm in diameter and weighing 100 g, with amyloid deposits accounting for 70% of the tumor volume.
  • On pathological evaluation, the tumor was classified as an insulinoma of uncertain biological behavior.
  • In addition to describing the clinical presentation and operative findings, criteria for determining malignancy are outlined, a detailed pathological description is presented, and the 2000 World Health Organization Classification for Pancreatic Endocrine Neoplasms is reviewed.
  • [MeSH-major] Insulinoma / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15522939.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / C-Peptide; 0 / Ki-67 Antigen
  •  go-up   go-down


87. Timmers HJ, Brouwers FM, Hermus AR, Sweep FC, Verhofstad AA, Verbeek AL, Pacak K, Lenders JW: Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer; 2008 Dec;15(4):1127-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma.
  • The treatment of choice for non-metastatic pheochromocytoma is surgical resection.
  • Its goals are to abolish catecholamine hypersecretion, normalize blood pressure, and prevent further tumor growth or progression to metastatic disease.
  • We here report a retrospective study on the long-term outcome after surgery for apparently benign pheochromocytoma at the Radboud University Nijmegen Medical Centre.
  • Survival was compared with survival of a matched reference population.
  • Two patients experienced a benign recurrence. Mean+/-s.d. follow-up was 10.2+/-7.5 (median 9, range 1-38) years.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Cardiovascular Diseases / mortality. Life Expectancy. Pheochromocytoma / secondary. Pheochromocytoma / surgery
  • [MeSH-minor] Adult. Aged. Blood Pressure. Catecholamines / blood. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824558.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catecholamines
  •  go-up   go-down


88. Stratakis CA: Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome). Endocr Dev; 2008;13:117-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of benign adrenocortical tumors associated with CS are associated with defects of the cAMP signaling pathway, whereas adrenal cancer is linked to aberrant expression of growth factors and germline or somatic mutations of tumor suppressor genes such as TP53.
  • [MeSH-major] Adenoma / complications. Adrenal Cortex Neoplasms / complications. Adrenal Glands / pathology. Adrenocorticotropic Hormone / physiology. Cushing Syndrome / etiology
  • [MeSH-minor] Algorithms. Cyclic AMP / physiology. Humans. Hyperplasia / complications. Hyperplasia / diagnosis. Hyperplasia / genetics. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1163-7 [9543134.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1274-8 [9100606.001]
  • [Cites] Endocr Rev. 1998 Oct;19(5):647-72 [9793762.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):1122-8 [10084605.001]
  • [Cites] Ann Intern Med. 1999 Oct 19;131(8):585-91 [10523219.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):794-800 [16767104.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11571-5 [17178847.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2415-8 [17554125.001]
  • [Cites] Pediatrics. 2007 Sep;120(3):e575-86 [17698579.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):219-25 [17940443.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):748-57 [17955016.001]
  • [Cites] Surgery. 2007 Dec;142(6):1011-21; discussion 1011-21 [18063089.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):750-2 [18272904.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):89-92 [10973256.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3262-5 [10999819.001]
  • [Cites] Lancet. 2001 Mar 10;357(9258):783-91 [11253984.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5 [11481490.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:112-8 [12381546.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3931-7 [12915689.001]
  • [Cites] Trends Endocrinol Metab. 2003 Nov;14(9):404-10 [14580759.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3173-82 [15240590.001]
  • [Cites] J Pediatr Surg. 1971 Apr;6(2):169-75 [4325361.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):418-22 [8106630.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Nov;77(5):1308-12 [8077325.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Oct;79(4):1082-5 [7962277.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):791-803 [7862184.001]
  • [Cites] Horm Metab Res. 1998 Jun-Jul;30(6-7):456-63 [9694579.001]
  • (PMID = 18493137.001).
  • [ISSN] 1421-7082
  • [Journal-full-title] Endocrine development
  • [ISO-abbreviation] Endocr Dev
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 HD000642-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; E0399OZS9N / Cyclic AMP
  • [Number-of-references] 33
  • [Other-IDs] NLM/ NIHMS307822; NLM/ PMC3132884
  •  go-up   go-down


89. Louiset E, Isvi K, Gasc JM, Duparc C, Cauliez B, Laquerrière A, Kuhn JM, Lefebvre H: Ectopic expression of serotonin7 receptors in an adrenocortical carcinoma co-secreting renin and cortisol. Endocr Relat Cancer; 2008 Dec;15(4):1025-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abnormal expression of membrane receptors has been previously described in benign adrenocortical neoplasms causing Cushing's syndrome.
  • Tumor explants were obtained at surgery and processed for immunohistochemistry, in situ hybridization and cell culture studies.
  • In addition, immunohistochemistry showed the occurrence of 5-HT(7) receptor-like immunoreactivity in carcinoma cells. mRNAs encoding renin as well as renin-like immunoreactivity were detected in endothelial and tumor cells.
  • The effects of 5-HT on adrenocortical tumor cells included a paradoxical inhibitory action on renin production and a stimulatory action on cortisol secretion involving 5-HT(7) receptors.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Hydrocortisone / metabolism. Receptors, Serotonin / metabolism. Renin / metabolism
  • [MeSH-minor] Adrenocorticotropic Hormone / pharmacology. Angiotensin II / pharmacology. Cushing Syndrome / metabolism. Cushing Syndrome / pathology. Female. Hormones / pharmacology. Humans. Immunoenzyme Techniques. In Situ Hybridization. Mast Cells / drug effects. Mast Cells / metabolism. Middle Aged. Phenols / pharmacology. Serotonin / pharmacology. Sulfonamides / pharmacology. Tumor Cells, Cultured / drug effects. Vasoconstrictor Agents / pharmacology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708508.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hormones; 0 / Phenols; 0 / Receptors, Serotonin; 0 / SB 269970; 0 / Sulfonamides; 0 / Vasoconstrictor Agents; 0 / serotonin 7 receptor; 11128-99-7 / Angiotensin II; 333DO1RDJY / Serotonin; 9002-60-2 / Adrenocorticotropic Hormone; EC 3.4.23.15 / Renin; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


90. Sugimoto M, Yasuda H, Koda K, Suzuki M, Yamazaki M, Tezuka T, Kosugi C, Higuchi R, Takenoue T, Yamamoto S, Watayo Y, Yagawa Y, Tsuchiya T: Virtual CO2 MDCT pancreatography: a new feasible technique for minimally invasive pancreatectomy in intraductal papillary mucinous neoplasms. Hepatogastroenterology; 2008 Jan-Feb;55(81):270-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virtual CO2 MDCT pancreatography: a new feasible technique for minimally invasive pancreatectomy in intraductal papillary mucinous neoplasms.
  • BACKGROUND/AIMS: Less invasive pancreatic head resection, such as duodenum-preserving pancreatic head resection (DPPHR) has been introduced for the treatment of pancreatoduodenal lesions, especially for benign conditions, for reducing surgical stress and maintaining exocrine and endocrine function of the residual pancreas in consideration of postoperative quality of life (QOL).
  • METHODOLOGY: We investigated the feasibility of a new technique employing three-dimensional (3D) virtual pancreatography using multi-detector CT (MDCT) with carbon dioxide (CO2) gas as a negative contrast agent for detection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas requiring minimally invasive surgery.
  • For localizing diagnosis of these small and multiple pancreatic cysts, we placed an endoscopic pancreatic stent (EPS), and MDCT with injection of CO2 via EPS was examined for the virtual CO2 pancreatography, consisting of OsiriX software system employing 3D virtual anatomic reconstruction with CO2 gas as a negative contrast agent.
  • We performed DPPHR, and surgical margin of the patient's remnant pancreas was determined as non-malignant by intraoperative histology.
  • There was no residual pancreatic cyst and tumor after surgery.
  • The resected tumor was diagnosed as branch duct type intraductal papillary mucinous adenocarcinoma.
  • According to our minimally invasive DPPHR obtained by virtual CO2 pancreatography, the pancreatic endocrine and exocrine functions of this patient were maintained at almost the same levels as those in his preoperative status.
  • With respect to preservation of the endocrine and exocrine functions of the pancreas, DPPHR is a highly effective surgical procedure due to limited surgical resection.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507123.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


91. Yang CY, Chou CW, Lin MB, Li CF: Schwannomas of the left adrenal gland and posterior mediastinum. J Chin Med Assoc; 2009 Feb;72(2):83-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Schwannomas of the left adrenal gland and posterior mediastinum.
  • Schwannoma is a rare tumor of neural crest cell origin.
  • The laboratory findings and endocrine studies were all within normal limits.
  • Pathologic studies showed a picture of benign schwannoma.
  • In conclusion, preoperative differentiation of benign schwannoma from malignant peripheral nerve sheath tumor or other tumors is important for good prognosis.
  • Total excision of benign schwannoma is associated with favourable outcome in patients.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Mediastinal Neoplasms / diagnosis. Neurilemmoma / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251536.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


92. Santarpia L, Sarlis NJ, Santarpia M, Sherman SI, Trimarchi F, Benvenga S: Mosaicism in von Hippel-Lindau disease: an event important to recognize. J Cell Mol Med; 2007 Nov-Dec;11(6):1408-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • von Hippel-Lindau disease (VHL) is an autosomal dominant, familial neoplastic disorder with variable interfamilial and intrafamilial expression.
  • VHL is characterized by pre-disposition to development of a combination of benign and malignant tumours affecting multiple organs.
  • The real incidence of mosaicism is still unclear and the identification of mosaicism has important consequences in genetic counseling of VHL patients who appear to have de novo VHL mutations and should be considered when evaluating patients with isolated VHL-related tumours.
  • Our results strongly suggest a complete and extensive clinical examination in the parents of each patient affected by an apparently de novo VHL germline mutation.
  • We recommend performing a mutation screening of both parents of a proband with techniques that permit detection of low percentages of mosaicism before concluding that the proband has a de novo VHL mutation.
  • [MeSH-minor] Adult. Base Sequence. Child. Chromatography, High Pressure Liquid. DNA Mutational Analysis. Exons / genetics. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Molecular Sequence Data. Nucleic Acid Denaturation. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205710.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ PMC4401302
  •  go-up   go-down


93. Ertorer ME, Tutuncu NB, Ozyilkan O: Incidental papillary microcarcinoma of the thyroid. Asian Pac J Cancer Prev; 2007 Oct-Dec;8(4):631-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillary microcarcinoma (PMC) is a thyroid tumor measuring 10mm or less in maximum diameter and comprise up to 30% of all papillary thyroid cancers.
  • The incidence of such incidental cancers found in surgical specimens of benign thyroid diseases is high.
  • There is an ongoing discussion among endocrinologists, endocrine surgeons and nuclear medicine specialists about the optimal therapeutic strategy for the patients with IPC<or=10mm.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Incidental Findings. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260743.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Thailand
  • [Number-of-references] 27
  •  go-up   go-down


94. Kanehara H, Bando Y, Tomita M, Kontani M, Takegoshi Y, Tanaka N: Myxedema ascites with an extremely elevated CA125 Level: a case report. Endocr J; 2007 Aug;54(4):601-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carbohydrate antigen 125 (CA125) is a tumor-marker frequently associated with ovarian malignancies; however, benign gynecologic conditions (e.g. ovarian cysts) commonly cause a smaller increase in CA125 levels.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Female. Humans. Thyroxine / therapeutic use

  • Genetic Alliance. consumer health - Myxedema.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641444.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


95. Shah OJ, Robbani I, Nazir P, Khan AB: Central pancreatectomy: a new technique for resection of selected pancreatic tumors. Hepatobiliary Pancreat Dis Int; 2009 Feb;8(1):93-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For small benign tumors enucleation is not usually feasible due to their size and localization; then pancreatectomy is often needed.
  • Central pancreatectomy consists of a limited resection of the midportion of the pancreas and can be offered in benign and low-grade malignant tumors of the neck of the pancreas.
  • RESULTS: Four patients, two with serous cystadenoma, and one with an islet cell tumor, and one with a hydatid cyst, were identified for the procedure.
  • The mean tumor size was 3 cm, the mean operative time was 217.5 minutes, and the mean blood loss was 382.5 ml.
  • No endocrine or exocrine deficiency was observed in any patient during a mean follow-up of 22.7 months.
  • CONCLUSIONS: Central pancreatectomy is a procedure that offers excellent results in benign and low-grade malignant tumors.
  • It preserves functional elements (endocrine and exocrine) of the pancreas and also eliminates the infective and hematological effects of splenectomy.
  • [MeSH-major] Cystadenoma / surgery. Echinococcosis / surgery. Pancreas / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208523.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  •  go-up   go-down


96. Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M: An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg; 2006 Dec;244(6):845-51; discussion 852-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors.
  • The diagnosis of PETs was based on clinical symptoms, biochemical tests, and histopathology.
  • The initial procedures comprised 27 resections of the primary tumor and 6 explorative laparotomies; 28 of all reoperations were resections of distant metastases, including 15 liver resections; 19 resections of the pancreas or duodenum were performed during reoperations.
  • All 6 patients with benign tumors are still alive.
  • The survival rate was significantly related to the patients age at time of initial operation and better in patients younger than 50 years compared with patients older than 50 years (P = 0.0007), and the presence or development of metastases (none or lymph node metastases versus distant metastases: P = 0.01).
  • [MeSH-major] Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Nov;24(11):1418-24 [11038216.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • [Cites] Cancer Control. 2002 Jan-Feb;9(1):67-79 [11907468.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):855-62 [12417506.001]
  • [Cites] Surgery. 2002 Dec;132(6):976-82; discussion 982-3 [12490844.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):29-37 [12831921.001]
  • [Cites] Arch Surg. 2003 Aug;138(8):859-66 [12912744.001]
  • [Cites] Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5 [14668741.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Apr 23;129(17):941-6 [15083396.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):757-73 [15492556.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1502-22 [2443618.001]
  • [Cites] Surgery. 1988 Dec;104(6):1011-7 [2904180.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):393-8; discussion 398-9 [1973323.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Aug;73(2):281-7 [1677362.001]
  • [Cites] Arch Surg. 1993 Jun;128(6):683-90 [8099273.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):320-8; discussion 328-30 [7916560.001]
  • [Cites] World J Surg. 1998 Jun;22(6):581-6; discussion 586-7 [9597932.001]
  • [Cites] World J Surg. 1998 Jul;22(7):666-71; discussion 671-2 [9606279.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3 [9660030.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):495-500 [9681848.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):286-93 [9922308.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):615-30 [10080607.001]
  • [Cites] J Am Coll Surg. 2000 Apr;190(4):432-45 [10757381.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1353-60 [11038206.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):36-42; discussion 42-3 [7817996.001]
  • [Cites] World J Surg. 1996 Sep;20(7):908-14; discussion 914-5 [8678970.001]
  • [Cites] Surgery. 1996 Dec;120(6):1055-62; discussion 1062-3 [8957495.001]
  • [Cites] Gut. 2005 Feb;54(2):289-96 [15647196.001]
  • [Cites] Surgery. 2004 Dec;136(6):1205-11 [15657577.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):170-85 [15719379.001]
  • [Cites] Chirurg. 2005 Mar;76(3):217-26 [15688179.001]
  • [Cites] Ann Surg. 2005 May;241(5):776-83; discussion 783-5 [15849513.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):577-83 [16183528.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):699-704 [16253894.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):753-81 [16253899.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):783-98 [16253900.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):819-30 [16253903.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):757-64, discussion 764-6 [16327485.001]
  • [Cites] Surgery. 2001 Feb;129(2):170-5 [11174710.001]
  • (PMID = 17122609.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1856628
  •  go-up   go-down


97. Darby S, Stockley J, Khan MM, Robson CN, Leung HY, Gnanapragasam VJ: Expression of GnRH type II is regulated by the androgen receptor in prostate cancer. Endocr Relat Cancer; 2007 Sep;14(3):613-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GnRH II protein was equally expressed in benign (73%) and malignant (78%) biopsies studied in a prostate tissue microarray (P = 0.779).
  • GnRH II was, however, significantly reduced in tumour biopsies following hormone ablation.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Gonadotropin-Releasing Hormone / analogs & derivatives. Prostatic Neoplasms / genetics. Receptors, Androgen / physiology
  • [MeSH-minor] Androgens / pharmacology. Animals. Base Sequence. Binding Sites. Cell Proliferation / drug effects. Humans. Male. Mice. Mice, Nude. Molecular Sequence Data. Neoplasm Invasiveness. Neoplasms, Hormone-Dependent / genetics. Neoplasms, Hormone-Dependent / metabolism. Neoplasms, Hormone-Dependent / pathology. Response Elements. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914092.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500966
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Androgens; 0 / Receptors, Androgen; 33515-09-2 / Gonadotropin-Releasing Hormone; 91097-16-4 / LHRH, His(5)-Trp(7)-Tyr(8)-
  •  go-up   go-down


98. Clark J, Carson W: A case of craniofacial polyostotic fibrous dysplasia. J Radiol Case Rep; 2010;4(9):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a patient with craniofacial polyostotic fibrous dysplasia.
  • It is occasionally associated with endocrine disorders such as McCune-Albright syndrome.
  • The benign pathology of this bone tumor belies its implications in the region of the skull base.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22470752.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303398
  • [Keywords] NOTNLM ; Craniofacial / Fibrous Dysplasia / Optic Nerve Decompression / Polyostotic
  •  go-up   go-down


99. Shin LK, Brant-Zawadzki G, Kamaya A, Jeffrey RB: Intraoperative ultrasound of the pancreas. Ultrasound Q; 2009 Mar;25(1):39-48; quiz 48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This pictorial essay will review common benign and malignant pancreatic processes including the following: pancreatic ductal adenocarcinoma, pancreatitis, endocrine tumors, mucinous cystic neoplasm, intraductal papillary mucinous neoplasm, serous cystadenoma, and solid pseudopapillary tumor.
  • (1) identification of insulinoma(s) which are not detectable preoperatively, (2) identification of the pancreatic duct to determine dissection planes for chronic pancreatitis surgery (eg, Puestow procedure) and for tumor resection, and (3) staging purposes for malignant disease.

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276960.001).
  • [ISSN] 1536-0253
  • [Journal-full-title] Ultrasound quarterly
  • [ISO-abbreviation] Ultrasound Q
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


100. Bordi C, D'Adda T, Azzoni C, Pizzi S, Bottarelli L, Mormandi F, Antonetti T, Luong TV, Rindi G: Criteria for malignancy in gastrointestinal endocrine tumors. Endocr Pathol; 2006;17(2):119-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for malignancy in gastrointestinal endocrine tumors.
  • In contrast with the large amount of data generated from endocrine tumors of the pancreas, sparse and mostly unconfirmed data are available on the criteria for the assessment of malignancy risk and patient outcome in endocrine tumors of the gastrointestinal tract.
  • In these conditions the 2000 WHO classification with its standardized scheme of pathologic report constitutes a framework facilitating the assessment of tumor malignancy and has been regarded as useful for clinical purposes, providing the basis for proper management of the patients and for the design of treatment protocols.
  • The classification is based on a combination of pathological and clinical features with parameters specific for each organ in which the endocrine tumors originate.
  • (1) well-differentiated endocrine tumors, further subdivided into tumors with benign and with uncertain behavior;.
  • (2) well-differentiated endocrine carcinomas, low grade; and (3) poorly differentiated endocrine carcinomas, high grade.
  • In this review the differential tumor characteristics between the different categories are summarized.
  • Moreover, the relevance of additional features with respect to tumor prognostication, chiefly the Ki-67 proliferation index and malignancy-associated genetic changes, is discussed with emphasis on the discrepancies emerging between tumors of foregut and of midgut origin.
  • [MeSH-major] Endocrine Gland Neoplasms / classification. Endocrine Gland Neoplasms / diagnosis. Gastrointestinal Neoplasms / classification. Gastrointestinal Neoplasms / diagnosis. Neoplasm Invasiveness / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Ki-67 Antigen. Mitotic Index. Prognosis. World Health Organization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Histopathology. 2004 Oct;45(4):384-92 [15469477.001]
  • [Cites] World J Surg. 1998 Mar;22(3):309-18 [9494425.001]
  • [Cites] Q J Nucl Med. 2000 Mar;44(1):3-12 [10932597.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1903-11 [11395364.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1787-94 [10595906.001]
  • [Cites] Tumour Biol. 1992;13(1-2):27-35 [1317054.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1094-101 [11679944.001]
  • [Cites] J Pathol. 2002 Apr;196(4):401-7 [11920735.001]
  • [Cites] Yale J Biol Med. 1998 May-Aug;71(3-4):273-84 [10461358.001]
  • [Cites] Cancer. 1971 Oct;28(4):990-8 [4106849.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):285-92 [11196176.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):323-33 [8982376.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Dec;32(4):364-72 [11746977.001]
  • [Cites] Hum Pathol. 1988 May;19(5):580-5 [2453443.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1803-8 [11337378.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):258-64 [10502325.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):706-11 [14608896.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1273-82 [12973852.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1145-53 [15316313.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;413(5):387-98 [2845642.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1765-75 [15755998.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):311-5 [9927038.001]
  • [Cites] J Pathol. 1998 Sep;186(1):41-50 [9875139.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):532-42 [10029611.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:1-12 [15153415.001]
  • [Cites] Am J Pathol. 1989 Dec;135(6):1065-72 [2480712.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] J Pathol. 1998 Aug;185(4):389-93 [9828837.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):472-8 [11257621.001]
  • [Cites] Cancer. 1983 Jan 15;51(2):277-82 [6821817.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S8-19 [7762739.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;419(6):463-8 [1750193.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):532-8 [11920612.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):404-10 [9218518.001]
  • [Cites] J Pathol. 1999 Nov;189(3):394-401 [10547602.001]
  • [Cites] J Pathol. 2001 Aug;194(4):451-8 [11523053.001]
  • [Cites] J Pathol. 2005 Aug;206(4):409-16 [15887288.001]
  • [Cites] Am J Clin Pathol. 1990 Feb;93(2):273-6 [1689098.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):437-50 [14713256.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Sep;1(3):323-33 [11901838.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):947-57 [14871972.001]
  • (PMID = 17159244.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  • [Number-of-references] 51
  •  go-up   go-down






Advertisement